Jos H. Beijnen - Publications

Affiliations: 
Pharmacy Utrecht University, Utrecht, Netherlands 
Area:
Analytical medicinal toxicology
Website:
http://profs.library.uu.nl/index.php/profrec/getprofdata/126/2/4/0

500 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

PUBLICATION UPDATES TEMPORARILY DISABLED DURING DATABASE UPDATE, SORRY!

Year Citation  Score
2021 Li W, Sparidans RW, Martins MLF, El-Lari M, Lebre MC, van Tellingen O, Beijnen JH, Schinkel AH. ABCB1 and ABCG2 restrict brain and testis accumulation and, alongside CYP3A, limit oral availability of the novel TRK inhibitor selitrectinib. Molecular Cancer Therapeutics. PMID 33785654 DOI: 10.1158/1535-7163.MCT-20-0705  0.76
2021 Nijstad AL, Tibben MM, Gebretensae A, Rosing H, de Vos-Kerkhof E, Zwaan CM, Huitema ADR, Beijnen JH. Development and validation of a combined liquid chromatography tandem-mass spectrometry assay for the quantification of aprepitant and dexamethasone in human plasma to support pharmacokinetic studies in pediatric patients. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 1171: 122639. PMID 33756449 DOI: 10.1016/j.jchromb.2021.122639  1
2021 Vermunt MAC, van der Heijden LT, Hendrikx JJMA, Schinkel AH, de Weger VA, van der Putten E, van Triest B, Bergman AM, Beijnen JH. Pharmacokinetics of docetaxel and ritonavir after oral administration of ModraDoc006/r in patients with prostate cancer versus patients with other advanced solid tumours. Cancer Chemotherapy and Pharmacology. PMID 33744986 DOI: 10.1007/s00280-021-04259-5  0.76
2021 Duinkerken CW, de Weger VA, Dreschler WA, van der Molen L, Pluim D, Rosing H, Nuijen B, Hauptmann M, Beijnen JH, Balm AJM, de Boer JP, Burgers JA, Marchetti S, Schellens JHM, Zuur CL. Transtympanic Sodium Thiosulfate for Prevention of Cisplatin-Induced Ototoxicity: A Randomized Clinical Trial. Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology. PMID 33710154 DOI: 10.1097/MAO.0000000000003069  1
2021 Vermunt MAC, Robbrecht DGJ, Devriese LA, Janssen JM, Thijssen B, Keessen M, van Eijk M, Kessels R, Eskens FALM, Beijnen JH, Mehra N, Bergman AM. ModraDoc006, an oral docetaxel formulation in combination with ritonavir (ModraDoc006/r), in metastatic castration-resistant prostate cancer patients: A phase Ib study. Cancer Reports (Hoboken, N.J.). e1367. PMID 33709626 DOI: 10.1002/cnr2.1367  0.72
2021 van Eijk M, Pluim D, Dorlo TPC, Marchetti S, Huitema ADR, Beijnen JH. Investigating the influence of relevant pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of orally administered docetaxel combined with ritonavir. The Pharmacogenomics Journal. PMID 33649517 DOI: 10.1038/s41397-021-00213-z  0.92
2021 Ykema BLM, Bisseling TM, Spaander MCW, Moons LMG, van der Biessen-van Beek D, Saveur L, Kerst M, Mulder SF, de Wit R, Zweers D, Meijer GA, Beijnen JH, Lansdorp-Vogelaar I, van Leeuwen FE, Snaebjornsson P, et al. Diagnostic yield of colonoscopy surveillance in testicular cancer survivors treated with platinum-based chemotherapy: study protocol of a prospective cross-sectional cohort study. Bmc Gastroenterology. 21: 67. PMID 33579196 DOI: 10.1186/s12876-021-01639-2  0.68
2021 Rood JJM, Toraño JS, Somovilla VJ, Beijnen JH, Sparidans RW. Bioanalysis of erlotinib, its O-demethylated metabolites OSI-413 and OSI-420, and other metabolites by liquid chromatography-tandem mass spectrometry with additional ion mobility identification. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 1166: 122554. PMID 33540147 DOI: 10.1016/j.jchromb.2021.122554  0.72
2021 Geenen JJ, Dackus GM, Schouten PC, Pluim D, Marchetti S, Sonke GS, Jóźwiak K, Huitema AD, Beijnen JH, Schellens JH, Linn SC. A phase I dose-escalation study of two cycles carboplatin-olaparib followed by olaparib monotherapy in patients with advanced cancer. International Journal of Cancer. PMID 33539540 DOI: 10.1002/ijc.33498  0.84
2021 Martínez-Chávez A, Broeders J, Lebre MC, Tibben MT, Rosing H, Beijnen JH, Schinkel AH. The role of drug efflux and uptake transporters ABCB1 (P-gp), ABCG2 (BCRP) and OATP1A/1B and of CYP3A4 in the pharmacokinetics of the CDK inhibitor milciclib. European Journal of Pharmaceutical Sciences : Official Journal of the European Federation For Pharmaceutical Sciences. 159: 105740. PMID 33524505 DOI: 10.1016/j.ejps.2021.105740  1
2021 de Gooijer MC, Kemper EM, Buil LCM, Çitirikkaya CH, Buckle T, Beijnen JH, van Tellingen O. ATP-binding cassette transporters restrict drug delivery and efficacy against brain tumors even when blood-brain barrier integrity is lost. Cell Reports. Medicine. 2: 100184. PMID 33521698 DOI: 10.1016/j.xcrm.2020.100184  0.52
2021 Janssen JM, Van Calsteren K, Dorlo TPC, Halaska MJ, Fruscio R, Ottevanger P, Schröder CP, Boere I, Witteveen PO, Painter RC, Bekkers R, Drochytek V, Beijnen JH, Huitema ADR, Amant FCH. Population Pharmacokinetics of Docetaxel, Paclitaxel, Doxorubicin and Epirubicin in Pregnant Women with Cancer: A Study from the International Network of Cancer, Infertility and Pregnancy (INCIP). Clinical Pharmacokinetics. PMID 33506375 DOI: 10.1007/s40262-020-00961-4  0.92
2021 Vermunt MAC, de Weger VA, Janssen JM, Lopez-Yurda MI, Keessen M, Thijssen B, Rosing H, Huitema ADR, Beijnen JH, Marchetti S. Effect of Food on the Pharmacokinetics of the Oral Docetaxel Tablet Formulation ModraDoc006 Combined with Ritonavir (ModraDoc006/r) in Patients with Advanced Solid Tumours. Drugs in R&D. PMID 33464545 DOI: 10.1007/s40268-020-00336-x  1
2021 Ten Ham RMT, van Nuland M, Vreman RA, de Graaf LG, Rosing H, Bergman AM, Huitema ADR, Beijnen JH, Hövels AM. Cost-Effectiveness Assessment of Monitoring Abiraterone Levels in Metastatic Castration-Resistant Prostate Cancer Patients. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 24: 121-128. PMID 33431146 DOI: 10.1016/j.jval.2020.04.1838  1
2021 Janssen JM, Jacobs BAW, Roosendaal J, Derissen EJB, Marchetti S, Beijnen JH, Huitema ADR, Dorlo TPC. Population Pharmacokinetics of Intracellular 5-Fluorouridine 5'-Triphosphate and its Relationship with Hand-and-Foot Syndrome in Patients Treated with Capecitabine. The Aaps Journal. 23: 23. PMID 33417061 DOI: 10.1208/s12248-020-00533-1  1
2020 Kip AE, Blesson S, Alves F, Wasunna M, Kimutai R, Menza P, Mengesha B, Beijnen JH, Hailu A, Diro E, Dorlo TPC. Low antileishmanial drug exposure in HIV-positive visceral leishmaniasis patients on antiretrovirals: an Ethiopian cohort study. The Journal of Antimicrobial Chemotherapy. PMID 33677546 DOI: 10.1093/jac/dkab013  0.6
2020 Retmana IA, Beijnen JH, Sparidans RW. Chromatographic bioanalytical assays for targeted covalent kinase inhibitors and their metabolites. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 1162: 122466. PMID 33316750 DOI: 10.1016/j.jchromb.2020.122466  0.72
2020 Hendrikx JJMA, Beijnen JH, Huitema ADR. Is Bodyweight-Based Dosing Truly Better Than Flat Dosing for Panitumumab? [Letter]. Clinical Pharmacology : Advances and Applications. 12: 177-178. PMID 33162757 DOI: 10.2147/CPAA.S282866  0.92
2020 Bruin MAC, Dekker D, Venekamp N, Tibben M, Rosing H, de Lange DW, Beijnen JH, Huitema ADR. Toxicological analysis of azide and cyanide for azide intoxications using gas chromatography. Basic & Clinical Pharmacology & Toxicology. PMID 33090684 DOI: 10.1111/bcpt.13523  1
2020 Groenland SL, Martínez-Chávez A, van Dongen MGJ, Beijnen JH, Schinkel AH, Huitema ADR, Steeghs N. Clinical Pharmacokinetics and Pharmacodynamics of the Cyclin-Dependent Kinase 4 and 6 Inhibitors Palbociclib, Ribociclib, and Abemaciclib. Clinical Pharmacokinetics. PMID 33029704 DOI: 10.1007/s40262-020-00930-x  0.92
2020 de Weger VA, Vermunt MAC, Stuurman FE, Burylo AM, Damoiseaux D, Hendrikx JJMA, Sawicki E, Moes JJ, Huitema ADR, Nuijen B, Rosing H, Mergui-Roelvink M, Beijnen JH, Marchetti S. A Phase 1 Dose-Escalation Study of Low-Dose Metronomic Treatment With Novel Oral Paclitaxel Formulations in Combination With Ritonavir in Patients With Advanced Solid Tumors. Clinical Pharmacology in Drug Development. PMID 33021083 DOI: 10.1002/cpdd.880  1
2020 Knikman JE, Gelderblom H, Beijnen JH, Cats A, Guchelaar HJ, Henricks LM. Individualized dosing of fluoropyrimidine-based chemotherapy to prevent severe fluoropyrimidine-related toxicity - What are the options? Clinical Pharmacology and Therapeutics. PMID 33020924 DOI: 10.1002/cpt.2069  0.76
2020 Roseboom IC, Rosing H, Beijnen JH, Dorlo TPC. Skin tissue sample collection, sample homogenization, and analyte extraction strategies for liquid chromatographic mass spectrometry quantification of pharmaceutical compounds. Journal of Pharmaceutical and Biomedical Analysis. 191: 113590. PMID 33010602 DOI: 10.1016/j.jpba.2020.113590  1
2020 de Jong KA, van Breugel SJ, Hillebrand MJ, Rosing H, Huitema AD, Beijnen JH. Bottom-up sample preparation for the LC-MS/MS quantification of anti-cancer monoclonal antibodies in bio matrices. Bioanalysis. PMID 32975434 DOI: 10.4155/bio-2020-0204  1
2020 Heinhuis KM, IJzerman NS, Koenen AM, van der Graaf WTA, Haas RL, Beijnen JH, Huitema ADR, van Houdt WJ, Steeghs N. PropAngio study protocol: a neoadjuvant trial on the efficacy of propranolol monotherapy in cutaneous angiosarcoma-a proof of principle study. Bmj Open. 10: e039449. PMID 32912994 DOI: 10.1136/bmjopen-2020-039449  0.92
2020 Heinhuis KM, Barkman HJ, Beijnen JH, Hendrikx JJMA. A cost analysis study of the implementation of fixed-dosing of monoclonal antibodies in the Netherlands Cancer Institute. International Journal of Clinical Pharmacy. PMID 32909221 DOI: 10.1007/s11096-020-01131-z  0.76
2020 Roosendaal J, Heidebrecht T, Rosing H, Perrakis A, Beijnen JH. Quantitative LC-MS/MS analysis of 5-hydroxymethyl-2'-deoxyuridine to monitor the biological activity of J-binding protein. Analytical Biochemistry. 610: 113930. PMID 32866463 DOI: 10.1016/j.ab.2020.113930  1
2020 Heinhuis KM, IJzerman NS, van der Graaf WTA, Kerst JM, Schrage Y, Beijnen JH, Steeghs N, van Houdt WJ. Neoadjuvant Systemic Treatment of Primary Angiosarcoma. Cancers. 12. PMID 32806524 DOI: 10.3390/cancers12082251  0.64
2020 Martínez-Chávez A, Tibben MM, Broeders J, Rosing H, Schinkel AH, Beijnen JH. Development and validation of an LC-MS/MS method for the quantitative analysis of milciclib in human and mouse plasma, mouse tissue homogenates and tissue culture medium. Journal of Pharmaceutical and Biomedical Analysis. 190: 113516. PMID 32784092 DOI: 10.1016/j.jpba.2020.113516  1
2020 Palić S, Kip AE, Beijnen JH, Mbui J, Musa A, Solomos A, Wasunna M, Olobo J, Alves F, Dorlo TPC. Characterizing the non-linear pharmacokinetics of miltefosine in paediatric visceral leishmaniasis patients from Eastern Africa. The Journal of Antimicrobial Chemotherapy. PMID 32780098 DOI: 10.1093/jac/dkaa314  0.6
2020 van den Berg JH, Heemskerk B, van Rooij N, Gomez-Eerland R, Michels S, van Zon M, de Boer R, Bakker NAM, Jorritsma-Smit A, van Buuren MM, Kvistborg P, Spits H, Schotte R, Mallo H, Karger M, ... ... Beijnen JH, et al. Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up. Journal For Immunotherapy of Cancer. 8. PMID 32753545 DOI: 10.1136/jitc-2020-000848  0.8
2020 Hendrikx JJMA, Stuurman FE, Song JY, de Weger VA, Lagas JS, Rosing H, Beijnen JH, Schinkel AH, Schellens JHM, Marchetti S. No relation between docetaxel administration route and high-grade diarrhea incidence. Pharmacology Research & Perspectives. 8: e00633. PMID 32725720 DOI: 10.1002/prp2.633  1
2020 IJzerman NS, Groenland SL, Koenen AM, Kerst M, van der Graaf WTA, Rosing H, Beijnen JH, Huitema ADR, Steeghs N. Therapeutic drug monitoring of imatinib in patients with gastrointestinal stromal tumours - Results from daily clinical practice. European Journal of Cancer (Oxford, England : 1990). 136: 140-148. PMID 32688207 DOI: 10.1016/j.ejca.2020.05.025  1
2020 Groenland SL, Geel DR, Janssen JM, de Vries N, Rosing H, Beijnen JH, Burgers JA, Smit EF, Huitema ADR, Steeghs N. Exposure-response analyses of anaplastic lymphoma kinase inhibitors crizotinib and alectinib in non-small-cell lung cancer patients. Clinical Pharmacology and Therapeutics. PMID 32686074 DOI: 10.1002/cpt.1989  1
2020 Rood JJM, Jamalpoor A, van Hoppe S, van Haren MJ, Wasmann RE, Janssen MJ, Schinkel AH, Masereeuw R, Beijnen JH, Sparidans RW. Extrahepatic metabolism of ibrutinib. Investigational New Drugs. PMID 32623551 DOI: 10.1007/s10637-020-00970-x  0.76
2020 Roosendaal J, Rosing H, Beijnen JH. Stable Isotopically Labeled Intravenous Microdose Pharmacokinetic Trials as a Tool to Assess Absolute Bioavailability: Feasibility and Paradigm to Apply for Protein Kinase Inhibitors in Oncology. Clinical Pharmacology in Drug Development. PMID 32573110 DOI: 10.1002/cpdd.840  1
2020 Verheijen RB, Swart EL, Beijnen JH, Schellens JHM, Huitema ADR, Steeghs N. Correction to: Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization. Cancer Chemotherapy and Pharmacology. PMID 32524189 DOI: 10.1007/s00280-020-04090-4  1
2020 Heinhuis KM, In 't Veld SGJG, Dwarshuis G, van den Broek D, Sol N, Best MG, Coevorden FV, Haas RL, Beijnen JH, van Houdt WJ, Würdinger T, Steeghs N. RNA-Sequencing of Tumor-Educated Platelets, a Novel Biomarker for Blood-Based Sarcoma Diagnostics. Cancers. 12. PMID 32471035 DOI: 10.3390/cancers12061372  0.68
2020 Martínez-Chávez A, Rosing H, Gan C, Wang Y, Schinkel AH, Beijnen JH. Bioanalytical method for the simultaneous quantification of irinotecan and its active metabolite SN-38 in mouse plasma and tissue homogenates using HPLC-fluorescence. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 1149: 122177. PMID 32464539 DOI: 10.1016/j.jchromb.2020.122177  1
2020 Roosendaal J, Groenland SL, Rosing H, Lucas L, Venekamp N, Nuijen B, Huitema ADR, Beijnen JH, Steeghs N. Determination of the absolute bioavailability of oral imatinib using a stable isotopically labeled intravenous imatinib-d8 microdose. European Journal of Clinical Pharmacology. PMID 32430518 DOI: 10.1007/s00228-020-02888-y  1
2020 Şentürk R, Wang Y, Schinkel AH, Beijnen JH, Sparidans RW. Quantitative bioanalytical assay for the selective RET inhibitors selpercatinib and pralsetinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 1147: 122131. PMID 32416592 DOI: 10.1016/j.jchromb.2020.122131  0.76
2020 Janssen JM, Dorlo TPC, Beijnen JH, Huitema ADR. Evaluation of Extrapolation Methods to Predict Trough Concentrations to Guide Therapeutic Drug Monitoring of Oral Anticancer Drugs. Therapeutic Drug Monitoring. 42: 532-539. PMID 32384536 DOI: 10.1097/FTD.0000000000000767  0.92
2020 Roosendaal J, Jacobs BAW, Pluim D, Rosing H, de Vries N, van Werkhoven E, Nuijen B, Beijnen JH, Huitema ADR, Schellens JHM, Marchetti S. Phase I pharmacological study of continuous chronomodulated capecitabine treatment. Pharmaceutical Research. 37: 89. PMID 32382808 DOI: 10.1007/s11095-020-02828-6  1
2020 Aalbersberg EA, van Andel L, Geluk-Jonker MM, Beijnen JH, Stokkel MPM, Hendrikx JJMA. Automated synthesis and quality control of [Tc]Tc-PSMA for radioguided surgery (in a [Ga]Ga-PSMA workflow). Ejnmmi Radiopharmacy and Chemistry. 5: 10. PMID 32358637 DOI: 10.1186/s41181-020-00095-9  0.76
2020 Yu H, Janssen JM, de Weger VA, Nuijen B, Stuurman RE, Marchetti S, Schellens JHM, Beijnen JH, Dorlo TPC, Huitema ADR. Quantification of the pharmacokinetic-toxicodynamic relationship of oral docetaxel co-administered with ritonavir. Investigational New Drugs. PMID 32306204 DOI: 10.1007/s10637-020-00935-0  1
2020 Roosendaal J, Rosing H, Beijnen JH. Combining Isotopic Tracer Techniques to Increase Efficiency of Clinical Pharmacokinetic Trials in Oncology. Drugs in R&D. PMID 32300967 DOI: 10.1007/s40268-020-00304-5  1
2020 Li W, Perpinioti N, Schinkel AH, Beijnen JH, Sparidans RW. Bioanalytical assay for the new-generation ROS1/TRK/ALK inhibitor repotrectinib in mouse plasma and tissue homogenate using liquid chromatography-tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 1144: 122098. PMID 32278292 DOI: 10.1016/j.jchromb.2020.122098  0.76
2020 Huijberts SCFA, van Geel RMJM, van Brummelen EMJ, Opdam FL, Marchetti S, Steeghs N, Pulleman S, Thijssen B, Rosing H, Monkhorst K, Huitema ADR, Beijnen JH, Bernards R, Schellens JHM. Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer. Cancer Chemotherapy and Pharmacology. PMID 32274564 DOI: 10.1007/s00280-020-04066-4  1
2020 Wang J, Bruin MAC, Gan C, Lebre MC, Rosing H, Beijnen JH, Schinkel AH. Brain accumulation of tivozanib is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein) in mice. International Journal of Pharmaceutics. 119277. PMID 32234426 DOI: 10.1016/j.ijpharm.2020.119277  1
2020 Roseboom IC, Thijssen B, Rosing H, Mbui J, Beijnen JH, Dorlo TPC. Highly sensitive UPLC-MS/MS method for the quantification of paromomycin in human plasma. Journal of Pharmaceutical and Biomedical Analysis. 185: 113245. PMID 32199328 DOI: 10.1016/j.jpba.2020.113245  1
2020 Groenland SL, van Nuland M, Bergman AM, de Feijter JM, Dezentje VO, Rosing H, Beijnen JH, Huitema ADR, Steeghs N. Concomitant intake of abiraterone acetate and food to increase pharmacokinetic exposure: real life data from a therapeutic drug monitoring programme. European Journal of Cancer (Oxford, England : 1990). 130: 32-38. PMID 32172196 DOI: 10.1016/j.ejca.2020.02.012  1
2020 van Geel RMJM, van Brummelen EMJ, Eskens FALM, Huijberts SCFA, de Vos FYFL, Lolkema MPJK, Devriese LA, Opdam FL, Marchetti S, Steeghs N, Monkhorst K, Thijssen B, Rosing H, Huitema ADR, Beijnen JH, et al. Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer. British Journal of Cancer. PMID 32147669 DOI: 10.1038/s41416-020-0776-z  1
2020 Huijberts S, Wang L, de Oliveira RL, Rosing H, Nuijen B, Beijnen J, Bernards R, Schellens J, Wilgenhof S. Vorinostat in patients with resistant mutated advanced melanoma: a proof of concept study. Future Oncology (London, England). PMID 32125175 DOI: 10.2217/fon-2020-0023  1
2020 Wang Y, Sparidans RW, Li W, Lebre MC, Beijnen JH, Schinkel AH. OATP1A/1B, CYP3A, ABCB1, and ABCG2 limit oral availability of NTRK inhibitor larotrectinib, while ABCB1 and ABCG2 also restrict its brain accumulation. British Journal of Pharmacology. PMID 32087611 DOI: 10.1111/bph.15034  0.76
2020 Huijberts SC, van Geel RM, Bernards R, Beijnen JH, Steeghs N. Encorafenib, binimetinib and cetuximab combined therapy for patients with mutant metastatic colorectal cancer. Future Oncology (London, England). 16: 161-173. PMID 32027186 DOI: 10.2217/fon-2019-0748  0.84
2020 Heinhuis KM, Beijnen JH, Hendrikx JJMA. Follow up survey for implementation of fixed-dosing of monoclonal antibodies. International Journal of Clinical Pharmacy. PMID 32026351 DOI: 10.1007/s11096-020-00971-z  0.76
2020 Janssen JM, Dorlo TPC, Steeghs N, Beijnen JH, Hanff LM, van Eijkelenburg NKA, van der Lugt J, Zwaan CM, Huitema ADR. Pharmacokinetic Targets for Therapeutic Drug Monitoring of Small Molecule Kinase Inhibitors in Pediatric Oncology. Clinical Pharmacology and Therapeutics. PMID 32022898 DOI: 10.1002/cpt.1808  0.92
2020 Groenland SL, van Eerden RAG, Verheijen RB, de Vries N, Thijssen B, Rosing H, Beijnen JH, Koolen SLW, Mathijssen RHJ, Huitema ADR, Steeghs N. Cost-Neutral Optimization of Pazopanib Exposure by Splitting Intake Moments: A Prospective Pharmacokinetic Study in Cancer Patients. Clinical Pharmacokinetics. PMID 32020530 DOI: 10.1007/s40262-020-00863-5  1
2020 de Vries Schultink AHM, Bol K, Doornbos RP, Murat A, Wasserman E, Dorlo TPC, Schellens JHM, Beijnen JH, Huitema ADR. Population Pharmacokinetics of MCLA-128, a HER2/HER3 Bispecific Monoclonal Antibody, in Patients with Solid Tumors. Clinical Pharmacokinetics. PMID 32006223 DOI: 10.1007/s40262-020-00858-2  1
2020 van Bussel MTJ, Pluim D, Milojkovic Kerklaan B, Bol M, Sikorska K, Linders DTC, van den Broek D, Beijnen JH, Schellens JHM, Brandsma D. Circulating epithelial tumor cell analysis in CSF in patients with leptomeningeal metastases. Neurology. PMID 31907288 DOI: 10.1212/WNL.0000000000008751  1
2019 Bruin MAC, de Vries N, Lucas L, Rosing H, Huitema ADR, Beijnen JH. Development and validation of an integrated LC-MS/MS assay for therapeutic drug monitoring of five PARP-inhibitors. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 1138: 121925. PMID 31915109 DOI: 10.1016/j.jchromb.2019.121925  1
2019 Li W, Sparidans R, El-Lari M, Wang Y, Lebre MC, Beijnen JH, Schinkel AH. P-glycoprotein (ABCB1/MDR1) limits brain accumulation and Cytochrome P450-3A (CYP3A) restricts oral availability of the novel FGFR4 inhibitor fisogatinib (BLU-554). International Journal of Pharmaceutics. 118842. PMID 31759109 DOI: 10.1016/j.ijpharm.2019.118842  0.76
2019 Crombag MBS, Dorlo TPC, van der Pan E, van Straten A, Bergman AM, van Erp NP, Beijnen JH, Huitema ADR. Exposure to Docetaxel in the Elderly Patient Population: a Population Pharmacokinetic Study. Pharmaceutical Research. 36: 181. PMID 31732882 DOI: 10.1007/s11095-019-2706-4  0.92
2019 Knikman JE, Rosing H, Guchelaar HJ, Cats A, Beijnen JH. A review of the bioanalytical methods for the quantitative determination of capecitabine and its metabolites in biological matrices. Biomedical Chromatography : Bmc. e4732. PMID 31691313 DOI: 10.1002/bmc.4732  1
2019 van der Noll R, Jager A, Ang JE, Marchetti S, Mergui-Roelvink MWJ, Lolkema MP, de Jonge MJA, van der Biessen DA, Brunetto AT, Arkenau HT, Tchakov I, Beijnen JH, de Bono JS, Schellens JHM. Phase I study of continuous olaparib capsule dosing in combination with carboplatin and/or paclitaxel (Part 1). Investigational New Drugs. PMID 31667659 DOI: 10.1007/s10637-019-00856-7  1
2019 Jacobs BAW, Deenen MJ, Joerger M, Rosing H, de Vries N, Meulendijks D, Cats A, Beijnen JH, Schellens JHM, Huitema ADR. Pharmacokinetics of capecitabine and four metabolites in a heterogeneous population of cancer patients: a comprehensive analysis. Cpt: Pharmacometrics & Systems Pharmacology. PMID 31652031 DOI: 10.1002/psp4.12474  1
2019 van der Noll R, Jager A, Ang JE, Marchetti S, Mergui-Roelvink MWJ, de Bono JS, Lolkema MP, de Jonge MJA, van der Biessen DA, Brunetto AT, Arkenau HT, Tchakov I, Beijnen JH, De Grève J, Schellens JHM. Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2). Investigational New Drugs. PMID 31637669 DOI: 10.1007/s10637-019-00857-6  1
2019 Crombag MBS, Koolen SLW, Wijngaard S, Joerger M, Dorlo TPC, van Erp NP, Mathijssen RHJ, Beijnen JH, Huitema ADR. Does Older Age Lead to Higher Risk for Neutropenia in Patients Treated with Paclitaxel? Pharmaceutical Research. 36: 163. PMID 31617004 DOI: 10.1007/s11095-019-2697-1  0.92
2019 Roosendaal J, Rosing H, Lucas L, Gebretensae A, Huitema ADR, van Dongen MG, Beijnen JH, Oganesian A. Mass balance and metabolite profiling of C-guadecitabine in patients with advanced cancer. Investigational New Drugs. PMID 31605293 DOI: 10.1007/s10637-019-00854-9  1
2019 van Nuland M, Bergman AM, Rosing H, de Vries N, Huitema ADR, Beijnen JH. Exposure-Response Assessment of Enzalutamide and Its Major Metabolites in a Real-World Cohort of Patients with Metastatic Castration-Resistant Prostate Cancer. Pharmacotherapy. PMID 31596947 DOI: 10.1002/phar.2339  1
2019 Yu H, Janssen JM, Sawicki E, van Hasselt JGC, de Weger VA, Nuijen B, Schellens JHM, Beijnen JH, Huitema ADR. A Population Pharmacokinetic Model of Oral Docetaxel Coadministered With Ritonavir to Support Early Clinical Development. Journal of Clinical Pharmacology. PMID 31595980 DOI: 10.1002/jcph.1532  1
2019 Pluim D, Ros W, Miedema IHC, Beijnen JH, Schellens JHM. Multiparameter Flow Cytometry Assay for Quantification of Immune Cell Subsets, PD-1 Expression Levels and PD-1 Receptor Occupancy by Nivolumab and Pembrolizumab. Cytometry. Part a : the Journal of the International Society For Analytical Cytology. PMID 31407460 DOI: 10.1002/cyto.a.23873  1
2019 Bruin MAC, Rosing H, Lucas L, Wang J, Huitema ADR, Schinkel AH, Beijnen JH. Development and validation of an LC-MS/MS method with a broad linear dynamic range for the quantification of tivozanib in human and mouse plasma, mouse tissue homogenates, and culture medium. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 1125: 121723. PMID 31352204 DOI: 10.1016/j.jchromb.2019.121723  1
2019 Martínez-Chávez A, van Hoppe S, Rosing H, Lebre MC, Tibben M, Beijnen JH, Schinkel AH. P-glycoprotein limits ribociclib brain exposure and CYP3A4 restricts its oral bioavailability. Molecular Pharmaceutics. PMID 31329454 DOI: 10.1021/acs.molpharmaceut.9b00475  1
2019 Janssen JM, Dorlo TPC, Niewerth D, Wilhelm AJ, Zwaan CM, Beijnen JH, Attarbaschi A, Baruchel A, Fagioli F, Klingebiel T, De Moerloose B, Palumbo G, von Stackelberg A, Kaspers GJL, Huitema ADR. A Semi-Mechanistic Population Pharmacokinetic/Pharmacodynamic Model of Bortezomib in Pediatric Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. Clinical Pharmacokinetics. PMID 31313068 DOI: 10.1007/s40262-019-00803-y  0.92
2019 van Eijk M, Boosman RJ, Schinkel AH, Huitema ADR, Beijnen JH. Cytochrome P450 3A4, 3A5, and 2C8 expression in breast, prostate, lung, endometrial, and ovarian tumors: relevance for resistance to taxanes. Cancer Chemotherapy and Pharmacology. PMID 31309254 DOI: 10.1007/s00280-019-03905-3  0.92
2019 Li W, Tibben M, Wang Y, Lebre MC, Rosing H, Beijnen JH, Schinkel AH. P-glycoprotein (MDR1/ABCB1) controls brain accumulation and intestinal disposition of the novel TGF-β signaling pathway inhibitor galunisertib. International Journal of Cancer. PMID 31304590 DOI: 10.1002/ijc.32568  1
2019 Janssen JM, de Vries N, Venekamp N, Rosing H, Huitema ADR, Beijnen JH. Development and validation of a liquid chromatography-tandem mass spectrometry assay for nine oral anticancer drugs in human plasma. Journal of Pharmaceutical and Biomedical Analysis. 174: 561-566. PMID 31255856 DOI: 10.1016/j.jpba.2019.06.034  1
2019 van Nuland M, Janssen JM, van Hoek B, Rosing H, Beijnen JH, Bergman AM. Efficacy, Tolerance, and Plasma Levels of Abiraterone and Its Main Metabolites in a Patient With Metastatic Castration-resistant Prostate Cancer With a Hepatic Transplant. Clinical Genitourinary Cancer. PMID 31248829 DOI: 10.1016/j.clgc.2019.05.026  1
2019 de Weger VA, Stuurman FE, Koolen SL, Moes JJ, Hendrikx JJMA, Sawicki E, Thijssen B, Keessen M, Rosing H, Mergui-Roelvink M, Huitema ADR, Nuijen B, Beijnen JH, Schellens JHM, Marchetti S. A phase I dose escalation study of once weekly oral administration of docetaxel as ModraDoc001 capsule or ModraDoc006 tablet in combination with ritonavir. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31217201 DOI: 10.1158/1078-0432.CCR-17-2299  1
2019 van Nuland M, Rosing H, Schellens JHM, Beijnen JH. Bioanalytical LC-MS/MS validation of therapeutic drug monitoring assays in oncology. Biomedical Chromatography : Bmc. e4623. PMID 31215049 DOI: 10.1002/bmc.4623  1
2019 Braal CL, Beijnen JH, Koolen SLW, Oomen-de Hoop E, Steeghs N, Jager A, Huitema ADR, Mathijssen RHJ. Relevance of Endoxifen Concentrations: Absence of Evidence Is Not Evidence of Absence. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1900418. PMID 31211599 DOI: 10.1200/JCO.19.00418  0.92
2019 Martínez-Chávez A, Rosing H, Hillebrand M, Tibben M, Schinkel AH, Beijnen JH. Development and validation of a bioanalytical method for the quantification of the CDK4/6 inhibitors abemaciclib, palbociclib, and ribociclib in human and mouse matrices using liquid chromatography-tandem mass spectrometry. Analytical and Bioanalytical Chemistry. PMID 31209549 DOI: 10.1007/s00216-019-01932-w  1
2019 Crombag MBS, Haanen JBAG, Baas P, Beijnen JH, Huitema ADR. Treatment of older patients with immune checkpoint inhibitors in routine clinical care as compared to inclusion in pivotal registration trials. Journal of Geriatric Oncology. PMID 31208830 DOI: 10.1016/j.jgo.2019.06.001  0.92
2019 van Hoppe S, Jamalpoor A, Rood JJM, Wagenaar E, Sparidans RW, Beijnen JH, Schinkel AH. Brain accumulation of osimertinib and its active metabolite AZ5104 is restricted by ABCB1 (P-glycoprotein) and ABCG2 (Breast Cancer Resistance Protein). Pharmacological Research. 104297. PMID 31175939 DOI: 10.1016/j.phrs.2019.104297  0.76
2019 Groenland SL, Mathijssen RHJ, Beijnen JH, Huitema ADR, Steeghs N. Individualized dosing of oral targeted therapies in oncology is crucial in the era of precision medicine. European Journal of Clinical Pharmacology. PMID 31175385 DOI: 10.1007/s00228-019-02704-2  0.92
2019 Sparidans RW, Li W, Schinkel AH, Beijnen JH. Bioanalytical assay for the novel TRK inhibitor selitrectinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 1122: 78-82. PMID 31163324 DOI: 10.1016/j.jchromb.2019.05.026  0.76
2019 Arnamo AH, Huitema AD, Beijnen JH, Nuijen B. Use of leftovers of monoclonal antibody products after partial extraction - A microbiological safety study. Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners. 1078155219850297. PMID 31156055 DOI: 10.1177/1078155219850297  0.8
2019 van Bussel MTJ, Beijnen JH, Brandsma D. Intracranial antitumor responses of nivolumab and ipilimumab: a pharmacodynamic and pharmacokinetic perspective, a scoping systematic review. Bmc Cancer. 19: 519. PMID 31146733 DOI: 10.1186/s12885-019-5741-y  0.44
2019 Palić S, Bhairosing P, Beijnen JH, Dorlo TPC. Host-mediated activity of miltefosine in leishmaniasis through immunomodulation: a systematic review. Antimicrobial Agents and Chemotherapy. PMID 31036692 DOI: 10.1128/AAC.02507-18  0.6
2019 van Nuland M, Rosing H, Huitema ADR, Beijnen JH. Predictive Value of Microdose Pharmacokinetics. Clinical Pharmacokinetics. PMID 31030372 DOI: 10.1007/s40262-019-00769-x  1
2019 van Nuland M, Venekamp N, Wouters WME, van Rossum HH, Rosing H, Beijnen JH. LC-MS/MS assay for the quantification of testosterone, dihydrotestosterone, androstenedione, cortisol and prednisone in plasma from castrated prostate cancer patients treated with abiraterone acetate or enzalutamide. Journal of Pharmaceutical and Biomedical Analysis. 170: 161-168. PMID 30925273 DOI: 10.1016/j.jpba.2019.03.043  1
2019 Dogan-Topal B, Li W, Schinkel AH, Beijnen JH, Sparidans RW. Quantification of FGFR4 inhibitor BLU-554 in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 1110: 116-123. PMID 30802754 DOI: 10.1016/j.jchromb.2019.02.017  0.76
2019 de Vries Schultink AHM, Crombag MBS, van Werkhoven E, Otten HM, Bergman AM, Schellens JHM, Huitema ADR, Beijnen JH. Neutropenia and docetaxel exposure in metastatic castration-resistant prostate cancer patients: A meta-analysis and evaluation of a clinical cohort. Cancer Medicine. PMID 30802002 DOI: 10.1002/cam4.2003  1
2019 Roosendaal J, Wang K, Rosing H, Lucas L, Gebretensae A, Oganesian A, Schellens JHM, Beijnen JH, Lin ZJ. Development and validation of LC-MS/MS methods for the quantification of the novel anticancer agent guadecitabine and its active metabolite β‑decitabine in human plasma, whole blood and urine. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 1109: 132-141. PMID 30754019 DOI: 10.1016/j.jchromb.2019.01.011  1
2019 Crombag MBS, de Vries Schultink AHM, van Doremalen JGC, Otten HM, Bergman AM, Schellens JHM, Beijnen JH, Huitema ADR. Age-Associated Hematological Toxicity in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel in Clinical Practice. Drugs & Aging. PMID 30734241 DOI: 10.1007/s40266-019-00643-2  1
2019 Durmus S, van der Valk M, Teunissen SF, Song JY, Wagenaar E, Beijnen JH, Schinkel AH. ABC transporters Mdr1a/1b, Bcrp1, Mrp2 and Mrp3 determine the sensitivity to PhIP/DSS-induced colon carcinogenesis and inflammation. Archives of Toxicology. PMID 30701287 DOI: 10.1007/s00204-019-02394-w  0.76
2019 Li W, Sparidans RW, Wang Y, Lebre MC, Beijnen JH, Schinkel AH. Oral coadministration of elacridar and ritonavir enhances brain accumulation and oral availability of the novel ALK/ROS1 inhibitor lorlatinib. European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V. PMID 30660696 DOI: 10.1016/j.ejpb.2019.01.016  0.76
2019 van Nuland M, Venekamp N, de Vries N, de Jong KAM, Rosing H, Beijnen JH. Development and validation of an UPLC-MS/MS method for the therapeutic drug monitoring of oral anti-hormonal drugs in oncology. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 1106: 26-34. PMID 30639947 DOI: 10.1016/j.jchromb.2019.01.001  1
2019 Crombag MBS, de Vries Schultink AHM, Koolen SLW, Wijngaard S, Joerger M, Schellens JHM, Dorlo TPC, van Erp NP, Mathijssen RHJ, Beijnen JH, Huitema ADR. Impact of Older Age on the Exposure of Paclitaxel: a Population Pharmacokinetic Study. Pharmaceutical Research. 36: 33. PMID 30617624 DOI: 10.1007/s11095-018-2563-6  1
2019 Heinhuis KM, Ros W, Kok M, Steeghs N, Beijnen JH, Schellens JHM. Enhancing anti-tumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 30608567 DOI: 10.1093/annonc/mdy551  1
2019 Henricks LM, Lunenburg CATC, de Man FM, Meulendijks D, Frederix GWJ, Kienhuis E, Creemers GJ, Baars A, Dezentjé VO, Imholz ALT, Jeurissen FJF, Portielje JEA, Jansen RLH, Hamberg P, Ten Tije AJ, ... ... Beijnen JH, et al. A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy. European Journal of Cancer (Oxford, England : 1990). 107: 60-67. PMID 30544060 DOI: 10.1016/j.ejca.2018.11.010  1
2018 van Nuland M, Groenland S, Bergman AM, Rotmans JI, Rosing H, Beijnen JH, Huitema ADR. Plasma Levels of Enzalutamide and Its Main Metabolites in a Patient With Metastatic Castration-resistant Prostate Cancer Undergoing Hemodialysis. Clinical Genitourinary Cancer. PMID 30626533 DOI: 10.1016/j.clgc.2018.12.004  1
2018 Wang J, Gan C, Retmana IA, Sparidans RW, Li W, Lebre MC, Beijnen JH, Schinkel AH. P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) limit brain accumulation of the FLT3 inhibitor quizartinib in mice. International Journal of Pharmaceutics. PMID 30553002 DOI: 10.1016/j.ijpharm.2018.12.014  0.76
2018 Henricks LM, van Merendonk LN, Meulendijks D, Deenen MJ, Beijnen JH, de Boer A, Cats A, Schellens JHM. Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: A matched pair analysis. International Journal of Cancer. PMID 30485432 DOI: 10.1002/ijc.32022  1
2018 Sparidans RW, Wang Y, Schinkel AH, Schellens JHM, Beijnen JH. Quantitative bioanalytical assay for the tropomyosin receptor kinase inhibitor larotrectinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 1102: 167-172. PMID 30396050 DOI: 10.1016/j.jchromb.2018.10.023  1
2018 Pluim D, Ros W, van Bussel MTJ, Brandsma D, Beijnen JH, Schellens JHM. Enzyme linked immunosorbent assay for the quantification of nivolumab and pembrolizumab in human serum and cerebrospinal fluid. Journal of Pharmaceutical and Biomedical Analysis. 164: 128-134. PMID 30368118 DOI: 10.1016/j.jpba.2018.10.025  1
2018 Roosendaal J, Rosing H, Lucas L, Oganesian A, Schellens JHM, Beijnen JH. Development, validation, and clinical application of a high-performance liquid chromatography-tandem mass spectrometry assay for the quantification of total intracellular β-decitabine nucleotides and genomic DNA incorporated β-decitabine and 5-methyl-2'-deoxycytidine. Journal of Pharmaceutical and Biomedical Analysis. 164: 16-26. PMID 30366147 DOI: 10.1016/j.jpba.2018.10.001  1
2018 Henricks LM, Lunenburg CATC, de Man FM, Meulendijks D, Frederix GWJ, Kienhuis E, Creemers GJ, Baars A, Dezentjé VO, Imholz ALT, Jeurissen FJF, Portielje JEA, Jansen RLH, Hamberg P, Ten Tije AJ, ... ... Beijnen JH, et al. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. The Lancet. Oncology. PMID 30348537 DOI: 10.1016/S1470-2045(18)30686-7  1
2018 Jacobs BAW, Pluim D, van der Laan P, Tzani A, Beijnen JH, Schellens JHM. Development and validation of a quantitative method for thymidine phosphorylase activity in peripheral blood mononuclear cells. Nucleosides, Nucleotides & Nucleic Acids. 1-19. PMID 30285552 DOI: 10.1080/15257770.2018.1498270  1
2018 Crombag MBS, van Nuland M, Bergman AM, Rosing H, Schellens JHM, Huitema ADR, Beijnen JH. Impact of age on exposure to oral antiandrogen therapies in clinical practice. Prostate Cancer and Prostatic Diseases. PMID 30279580 DOI: 10.1038/s41391-018-0096-z  1
2018 Li W, Sparidans RW, Wang Y, Lebre MC, Beijnen JH, Schinkel AH. P-glycoprotein and Breast Cancer Resistance Protein restrict brigatinib brain accumulation and toxicity, and, alongside CYP3A, limit its oral availability. Pharmacological Research. PMID 30253203 DOI: 10.1016/j.phrs.2018.09.020  0.76
2018 de Gooijer MC, Buil LCM, Çitirikkaya CH, Hermans J, Beijnen JH, van Tellingen O. ABCB1 Attenuates the Brain Penetration of the PARP Inhibitor AZD2461. Molecular Pharmaceutics. PMID 30252484 DOI: 10.1021/acs.molpharmaceut.8b00742  0.52
2018 van Hoppe S, Rood JJM, Buil L, Wagenaar E, Sparidans RW, Beijnen JH, Schinkel AH. P-glycoprotein (MDR1/ABCB1) restricts brain penetration of the Bruton's tyrosine kinase inhibitor ibrutinib while Cytochrome P450-3A (CYP3A) limits its oral bioavailability. Molecular Pharmaceutics. PMID 30247919 DOI: 10.1021/acs.molpharmaceut.8b00702  0.76
2018 de Vries Schultink AHM, Huitema ADR, Beijnen JH. Therapeutic Drug Monitoring of endoxifen as an alternative for CYP2D6 genotyping in individualizing tamoxifen therapy. Breast (Edinburgh, Scotland). 42: 38-40. PMID 30153552 DOI: 10.1016/j.breast.2018.08.100  0.92
2018 Sparidans RW, Li W, Schinkel AH, Schellens JHM, Beijnen JH. Bioanalytical liquid chromatography-tandem mass spectrometric assay for the quantification of the ALK inhibitors alectinib, brigatinib and lorlatinib in plasma and mouse tissue homogenates. Journal of Pharmaceutical and Biomedical Analysis. 161: 136-143. PMID 30149189 DOI: 10.1016/j.jpba.2018.08.038  1
2018 Crombag MBS, van Doremalen JGC, Janssen JM, Rosing H, Schellens JHM, Beijnen JH, Steeghs N, Huitema ADR. Therapeutic Drug Monitoring of Small Molecule Kinase Inhibitors in Oncology in a Real-world Cohort Study: Does Age Matter? British Journal of Clinical Pharmacology. PMID 30068020 DOI: 10.1111/bcp.13725  1
2018 Henricks LM, Jacobs BAW, Meulendijks D, Pluim D, van den Broek D, de Vries N, Rosing H, Beijnen JH, Huitema ADR, Guchelaar HJ, Cats A, Schellens JHM. Food-effect study on uracil and dihydrouracil plasma levels as marker for dihydropyrimidine dehydrogenase activity in human volunteers. British Journal of Clinical Pharmacology. PMID 30047584 DOI: 10.1111/bcp.13719  1
2018 van Andel L, Rosing H, Schellens JH, Beijnen JH. Review of Chromatographic Bioanalytical Assays for the Quantitative Determination of Marine-Derived Drugs for Cancer Treatment. Marine Drugs. 16. PMID 30041477 DOI: 10.3390/md16070246  1
2018 de Gooijer MC, Zhang P, Buil LCM, Çitirikkaya CH, Thota N, Beijnen JH, van Tellingen O. Buparlisib is a brain penetrable pan-PI3K inhibitor. Scientific Reports. 8: 10784. PMID 30018387 DOI: 10.1038/s41598-018-29062-w  0.52
2018 van Nuland M, Vreman RA, Ten Ham RMT, de Vries Schultink AHM, Rosing H, Schellens JHM, Beijnen JH, Hövels AM. Cost-effectiveness of monitoring endoxifen levels in breast cancer patients adjuvantly treated with tamoxifen. Breast Cancer Research and Treatment. PMID 30006796 DOI: 10.1007/s10549-018-4886-8  1
2018 van Andel L, Rosing H, Tibben MM, Lucas L, Lubomirov R, Avilés P, Francesch A, Fudio S, Gebretensae A, Hillebrand MJX, Schellens JHM, Beijnen JH. Metabolite profiling of the novel anti-cancer agent, plitidepsin, in urine and faeces in cancer patients after administration of C-plitidepsin. Cancer Chemotherapy and Pharmacology. PMID 29974200 DOI: 10.1007/s00280-018-3637-1  1
2018 Kip AE, Wasunna M, Alves F, Schellens JHM, Beijnen JH, Musa AM, Khalil EAG, Dorlo TPC. Macrophage Activation Marker Neopterin: A Candidate Biomarker for Treatment Response and Relapse in Visceral Leishmaniasis. Frontiers in Cellular and Infection Microbiology. 8: 181. PMID 29911074 DOI: 10.3389/fcimb.2018.00181  1
2018 van Andel L, Rosing H, Lubomirov R, Avilés P, Fudio S, Tibben MM, Nan-Offeringa L, Schellens JHM, Beijnen JH. Development and validation of a liquid chromatography-tandem mass spectrometry assay for the quantification of lurbinectedin in human plasma and urine. Journal of Pharmaceutical and Biomedical Analysis. 158: 160-165. PMID 29883879 DOI: 10.1016/j.jpba.2018.05.053  1
2018 Groenland SL, van Nuland M, Verheijen RB, Schellens JHM, Beijnen JH, Huitema ADR, Steeghs N. Therapeutic Drug Monitoring of Oral Anti-Hormonal Drugs in Oncology. Clinical Pharmacokinetics. PMID 29862467 DOI: 10.1007/s40262-018-0683-0  1
2018 de Gooijer MC, de Vries NA, Buckle T, Buil LCM, Beijnen JH, Boogerd W, van Tellingen O. Improved Brain Penetration and Antitumor Efficacy of Temozolomide by Inhibition of ABCB1 and ABCG2. Neoplasia (New York, N.Y.). 20: 710-720. PMID 29852323 DOI: 10.1016/j.neo.2018.05.001  0.52
2018 Kip AE, Castro MDM, Gomez MA, Cossio A, Schellens JHM, Beijnen JH, Saravia NG, Dorlo TPC. Simultaneous population pharmacokinetic modelling of plasma and intracellular PBMC miltefosine concentrations in New World cutaneous leishmaniasis and exploration of exposure-response relationships. The Journal of Antimicrobial Chemotherapy. PMID 29757380 DOI: 10.1093/jac/dky143  1
2018 Wang L, Leite de Oliveira R, Huijberts S, Bosdriesz E, Pencheva N, Brunen D, Bosma A, Song JY, Zevenhoven J, Los-de Vries GT, Horlings H, Nuijen B, Beijnen JH, Schellens JHM, Bernards R. An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential. Cell. PMID 29754815 DOI: 10.1016/j.cell.2018.04.012  1
2018 Li W, Sparidans RW, Wang Y, Lebre MC, Wagenaar E, Beijnen JH, Schinkel AH. P-glycoprotein (MDR1/ABCB1) restricts brain accumulation and Cytochrome P450-3A (CYP3A) limits oral availability of the novel ALK/ROS1 inhibitor lorlatinib. International Journal of Cancer. PMID 29744867 DOI: 10.1002/ijc.31582  0.76
2018 de Vries Schultink AHM, Doornbos RP, Bakker ABH, Bol K, Throsby M, Geuijen C, Maussang D, Schellens JHM, Beijnen JH, Huitema ADR. Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose. Investigational New Drugs. PMID 29728897 DOI: 10.1007/s10637-018-0593-x  1
2018 Herbrink M, Groenland SL, Huitema ADR, Schellens JHM, Beijnen JH, Steeghs N, Nuijen B. Solubility and bioavailability improvement of pazopanib hydrochloride. International Journal of Pharmaceutics. 544: 181-190. PMID 29680279 DOI: 10.1016/j.ijpharm.2018.04.037  1
2018 Herbrink M, Nuijten M, Nuijen B, Huitema ADR, Beijnen JH, Hendriks VM, Blanken P, Janmohamed A, van den Brink W. Pharmacokinetics of Sustained-Release Oral Dexamphetamine Sulfate in Cocaine and Heroin-Dependent Patients. Journal of Clinical Psychopharmacology. 38: 212-217. PMID 29620701 DOI: 10.1097/JCP.0000000000000862  0.92
2018 Spatari C, Li W, Schinkel AH, Ragno G, Schellens JHM, Beijnen JH, Sparidans RW. Bioanalytical assay for the quantification of the ALK inhibitor lorlatinib in mouse plasma using liquid chromatography-tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 1083: 204-208. PMID 29550682 DOI: 10.1016/j.jchromb.2018.03.014  1
2018 Milroy LG, Koning B, Scheppingen DSV, Jager NGL, Beijnen JH, Koek J, Brunsveld L. A multi-gram-scale stereoselective synthesis of Z-endoxifen. Bioorganic & Medicinal Chemistry Letters. PMID 29548575 DOI: 10.1016/j.bmcl.2018.03.008  0.8
2018 Derissen EJB, Huitema ADR, Rosing H, Schellens JHM, Beijnen JH. Intracellular pharmacokinetics of gemcitabine, its deaminated metabolite 2',2'-difluorodeoxyuridine and their nucleotides. British Journal of Clinical Pharmacology. PMID 29451684 DOI: 10.1111/bcp.13557  1
2018 Jacobs BAW, Snoeren N, Samim M, Rosing H, de Vries N, Deenen MJ, Beijnen JH, Schellens JHM, Koopman M, van Hillegersberg R. The impact of liver resection on the dihydrouracil:uracil plasma ratio in patients with colorectal liver metastases. European Journal of Clinical Pharmacology. PMID 29430582 DOI: 10.1007/s00228-018-2426-4  1
2017 Verheijen RB, Thijssen B, Rosing H, Schellens JHM, Nan L, Venekamp N, Beijnen JH, Steeghs N, Huitema ADR. Fast and straightforward method for the quantification of pazopanib in human plasma using LC-MS/MS. Therapeutic Drug Monitoring. PMID 29256969 DOI: 10.1097/FTD.0000000000000479  1
2017 Burylo AM, de Weger VA, Stuurman FE, Beijnen JH, Schellens JHM. Enrichment of Circulating Endothelial Cells by CD34 Microbeads Followed by Enumeration Using Flow Cytometry. Thrombosis and Haemostasis. 117: 2356-2368. PMID 29212123 DOI: 10.1160/TH17-04-0254  1
2017 van Bussel MTJ, Pluim D, Bol M, Beijnen JH, Schellens JHM, Brandsma D. EpCAM-based assays for epithelial tumor cell detection in cerebrospinal fluid. Journal of Neuro-Oncology. PMID 29192390 DOI: 10.1007/s11060-017-2691-6  1
2017 van Andel L, Rosing H, Zhang Z, Hughes L, Kansra V, Sanghvi M, Tibben MM, Gebretensae A, Schellens JHM, Beijnen JH. Correction to: Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a 14C-microtracer and therapeutic dose in cancer patients. Cancer Chemotherapy and Pharmacology. PMID 29181573 DOI: 10.1007/s00280-017-3474-7  1
2017 Verheijen RB, Yaqub MM, Sawicki E, van Tellingen O, Lammertsma AA, Nuijen B, Schellens JHM, Beijnen JH, Huitema ADR, Hendrikse NH, Steeghs N. Molecular Imaging of ABCB1/ABCG2 Inhibition at the Human Blood Brain Barrier using Elacridar and 11C-Erlotinib PET. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 29175983 DOI: 10.2967/jnumed.117.195800  1
2017 Wang J, Gan C, Sparidans RW, Wagenaar E, van Hoppe S, Beijnen JH, Schinkel AH. P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) affect brain accumulation and intestinal disposition of encorafenib in mice. Pharmacological Research. PMID 29155017 DOI: 10.1016/j.phrs.2017.11.006  0.76
2017 de Gooijer MC, Buil LCM, Beijnen JH, van Tellingen O. ATP-binding cassette transporters limit the brain penetration of Wee1 inhibitors. Investigational New Drugs. PMID 29147815 DOI: 10.1007/s10637-017-0539-8  0.52
2017 Geenen JJJ, Linn SC, Beijnen JH, Schellens JHM. PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer. Clinical Pharmacokinetics. PMID 29063517 DOI: 10.1007/s40262-017-0587-4  1
2017 van Nuland M, Rosing H, de Vries J, Ovaa H, Schellens JHM, Beijnen JH. An LC-MS/MS method for quantification of the active abiraterone metabolite Δ(4)-abiraterone (D4A) in human plasma. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 1068: 119-124. PMID 29059586 DOI: 10.1016/j.jchromb.2017.10.033  1
2017 Verheijen RB, Swart LE, Beijnen JH, Schellens JHM, Huitema ADR, Steeghs N. Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization. Cancer Chemotherapy and Pharmacology. PMID 29051995 DOI: 10.1007/s00280-017-3463-x  1
2017 van Andel L, Rosing H, Zhang Z, Hughes L, Kansra V, Sanghvi M, Tibben MM, Gebretensae A, Schellens JHM, Beijnen JH. Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a (14)C-microtracer and therapeutic dose in cancer patients. Cancer Chemotherapy and Pharmacology. PMID 29043410 DOI: 10.1007/s00280-017-3455-x  1
2017 de Weger VA, Stuurman FE, Hendrikx JJMA, Moes JJ, Sawicki E, Huitema ADR, Nuijen B, Thijssen B, Rosing H, Keessen M, Mergui-Roelvink M, Beijnen JH, Schellens JHM, Marchetti S. A dose-escalation study of bi-daily once weekly oral docetaxel either as ModraDoc001 or ModraDoc006 combined with ritonavir. European Journal of Cancer (Oxford, England : 1990). 86: 217-225. PMID 29031170 DOI: 10.1016/j.ejca.2017.09.010  1
2017 de Groot JS, van Diest PJ, van Amersfoort M, Vlug EJ, Pan X, Ter Hoeve ND, Rosing H, Beijnen JH, Youssef SA, de Bruin A, Jonkers J, van der Wall E, Derksen PWB. Intraductal cisplatin treatment in a BRCA-associated breast cancer mouse model attenuates tumor development but leads to systemic tumors in aged female mice. Oncotarget. 8: 60750-60763. PMID 28977823 DOI: 10.18632/oncotarget.18490  1
2017 Dorlo TPC, Kip AE, Younis BM, Ellis SJ, Alves F, Beijnen JH, Njenga S, Kirigi G, Hailu A, Olobo J, Musa AM, Balasegaram M, Wasunna M, Karlsson MO, Khalil EAG. Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study. The Journal of Antimicrobial Chemotherapy. PMID 28961737 DOI: 10.1093/jac/dkx283  0.6
2017 de Gooijer MC, Zhang P, Weijer R, Buil LCM, Beijnen JH, van Tellingen O. The impact of P-glycoprotein and Breast Cancer Resistance Protein on the brain pharmacokinetics and pharmacodynamics of a panel of MEK inhibitors. International Journal of Cancer. PMID 28921565 DOI: 10.1002/ijc.31052  0.52
2017 van der Hiel B, Haanen JBAG, Stokkel MPM, Peeper DS, Jimenez CR, Beijnen JH, van de Wiel BA, Boellaard R, van den Eertwegh AJM. Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): study protocol of a phase II, open-label, multicenter study. Bmc Cancer. 17: 649. PMID 28915798 DOI: 10.1186/s12885-017-3626-5  0.4
2017 Janssen JM, Zwaan CM, Schellens JHM, Beijnen JH, Huitema ADR. Clinical trial simulations in paediatric oncology: A feasibility study from the Innovative Therapies for Children with Cancer Consortium. European Journal of Cancer (Oxford, England : 1990). 85: 78-85. PMID 28892776 DOI: 10.1016/j.ejca.2017.07.050  1
2017 Kort A, van Hoppe S, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH. Brain accumulation of ponatinib and its active metabolite N-desmethyl ponatinib is limited by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2). Molecular Pharmaceutics. PMID 28880088 DOI: 10.1021/acs.molpharmaceut.7b00257  0.76
2017 Retmana IA, Wang J, Schinkel AH, Schellens JHM, Beijnen JH, Sparidans RW. Liquid chromatography-tandem mass spectrometric assay for the quantitative determination of the tyrosine kinase inhibitor quizartinib in mouse plasma using salting-out liquid-liquid extraction. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 1061: 300-305. PMID 28772226 DOI: 10.1016/j.jchromb.2017.07.034  1
2017 Verheijen RB, Atrafi F, Schellens JHM, Beijnen JH, Huitema ADR, Mathijssen RHJ, Steeghs N. Pharmacokinetic Optimization of Everolimus Dosing in Oncology: A Randomized Crossover Trial. Clinical Pharmacokinetics. PMID 28762135 DOI: 10.1007/s40262-017-0582-9  1
2017 Kip AE, Schellens JHM, Beijnen JH, Dorlo TPC. Clinical Pharmacokinetics of Systemically Administered Antileishmanial Drugs. Clinical Pharmacokinetics. PMID 28756612 DOI: 10.1007/s40262-017-0570-0  1
2017 Hendrikx JJMA, Haanen JBAG, Voest EE, Schellens JHM, Huitema ADR, Beijnen JH. Fixed Dosing of Monoclonal Antibodies in Oncology. The Oncologist. PMID 28754722 DOI: 10.1634/theoncologist.2017-0167  1
2017 Verheijen RB, Yu H, Schellens JHM, Beijnen JH, Steeghs N, Huitema ADR. Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology. Clinical Pharmacology and Therapeutics. PMID 28699160 DOI: 10.1002/cpt.787  1
2017 Herbrink M, Schellens JHM, Beijnen JH, Nuijen B. Improving the solubility of nilotinib through novel spray-dried solid dispersions. International Journal of Pharmaceutics. PMID 28689964 DOI: 10.1016/j.ijpharm.2017.07.010  1
2017 de Groot JS, van Diest PJ, van Amersfoort M, Vlug EJ, Pan X, Ter Hoeve ND, Rosing H, Beijnen JH, Youssef SA, de Bruin A, Jonkers J, van der Wall E, Derksen PWB. Intraductal cisplatin treatment in a BRCA-associated breast cancer mouse model attenuates tumor development but leads to systemic tumors in aged female mice. Oncotarget. PMID 28644128 DOI: 10.18632/oncotarget.18490  1
2017 van Brummelen EMJ, de Boer A, Beijnen JH, Schellens JHM. BRAF Mutations as Predictive Biomarker for Response to Anti-EGFR Monoclonal Antibodies. The Oncologist. PMID 28576857 DOI: 10.1634/theoncologist.2017-0031  1
2017 Herbrink M, Nuijen B, Schellens JHM, Beijnen JH. High-Tech Drugs in Creaky Formulations. Pharmaceutical Research. PMID 28560695 DOI: 10.1007/s11095-017-2185-4  1
2017 Meulendijks D, Henricks LM, Jacobs BAW, Aliev A, Deenen MJ, de Vries N, Rosing H, van Werkhoven E, de Boer A, Beijnen JH, Mandigers CMPW, Soesan M, Cats A, Schellens JHM. Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity. British Journal of Cancer. PMID 28427087 DOI: 10.1038/bjc.2017.94  1
2017 de Gooijer MC, van den Top A, Bockaj I, Beijnen JH, Würdinger T, van Tellingen O. The G2 checkpoint-a node-based molecular switch. Febs Open Bio. 7: 439-455. PMID 28396830 DOI: 10.1002/2211-5463.12206  0.52
2017 van Andel L, Zhang Z, Lu S, Kansra V, Agarwal S, Hughes L, Tibben MM, Gebretensae A, Lucas L, Hillebrand MJ, Rosing H, Schellens JH, Beijnen JH. Human mass balance study and metabolite profiling of (14)C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer. Investigational New Drugs. PMID 28303528 DOI: 10.1007/s10637-017-0451-2  1
2017 van Hoppe S, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH. Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-gp/ABCB1) transport afatinib and restrict its oral availability and brain accumulation. Pharmacological Research. PMID 28288939 DOI: 10.1016/j.phrs.2017.01.035  0.76
2017 Verheijen RB, Beijnen JH, Schellens JH, Huitema AD, Steeghs N. Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing. Clinical Pharmacokinetics. PMID 28185218 DOI: 10.1007/s40262-017-0510-z  0.84
2017 Nijenhuis CM, Lucas L, Rosing H, Huitema AD, Mergui-Roelvink M, Jamieson GC, Fox JA, Mould DR, Schellens JH, Beijnen JH. Metabolism and disposition of the anticancer quinolone derivative vosaroxin, a novel inhibitor of topoisomerase II. Investigational New Drugs. PMID 28138829 DOI: 10.1007/s10637-017-0428-1  1
2017 van Andel L, Fudio S, Rosing H, Munt S, Miguel-Lillo B, González I, Tibben MM, de Vries N, de Vries Schultink AH, Schellens JH, Beijnen JH. Pharmacokinetics and excretion of (14)C-Plitidepsin in patients with advanced cancer. Investigational New Drugs. PMID 28111728 DOI: 10.1007/s10637-017-0432-5  1
2017 Sawicki E, Schellens JH, Beijnen JH, Nuijen B. Pharmaceutical development of an amorphous solid dispersion formulation of elacridar hydrochloride for proof-of-concept clinical studies. Drug Development and Industrial Pharmacy. 43: 584-594. PMID 28010129 DOI: 10.1080/03639045.2016.1274901  0.84
2016 Sawicki E, Hillebrand MJ, Rosing H, Schellens JHM, Nuijen B, Beijnen JH. Validation of a liquid chromatographic method for the pharmaceutical quality control of products containing elacridar. Journal of Pharmaceutical Analysis. 6: 268-275. PMID 29403992 DOI: 10.1016/j.jpha.2016.04.005  1
2016 de Krou S, Rosing H, Nuijen B, Schellens JH, Beijnen JH. Fast and adequate liquid chromatography-tandem mass spectrometric determination of Z-endoxifen serum levels for therapeutic drug monitoring. Therapeutic Drug Monitoring. PMID 28045782 DOI: 10.1097/FTD.0000000000000372  1
2016 de Vries Schultink AH, Alexi X, van Werkhoven E, Madlensky L, Natarajan L, Flatt SW, Zwart W, Linn SC, Parker BA, Wu AH, Pierce JP, Huitema AD, Beijnen JH. An Antiestrogenic Activity Score for tamoxifen and its metabolites is associated with breast cancer outcome. Breast Cancer Research and Treatment. PMID 28005246 DOI: 10.1007/s10549-016-4083-6  0.8
2016 Leijen S, van Geel RM, Sonke GS, de Jong D, Rosenberg EH, Marchetti S, Pluim D, van Werkhoven E, Rose S, Lee MA, Freshwater T, Beijnen JH, Schellens JH. Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 34: 4354-4361. PMID 27998224 DOI: 10.1200/JCO.2016.67.5942  0.84
2016 van Andel L, Zhang Z, Lu S, Kansra V, Agarwal S, Hughes L, Tibben MM, Gebretensae A, Rosing H, Schellens JH, Beijnen JH. Liquid chromatography-tandem mass spectrometry assay for the quantification of niraparib and its metabolite M1 in human plasma and urine. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 1040: 14-21. PMID 27898364 DOI: 10.1016/j.jchromb.2016.11.020  1
2016 Sawicki E, Verheijen RB, Huitema AD, van Tellingen O, Schellens JH, Nuijen B, Beijnen JH, Steeghs N. Clinical pharmacokinetics of an amorphous solid dispersion tablet of elacridar. Drug Delivery and Translational Research. PMID 27864786 DOI: 10.1007/s13346-016-0346-3  0.84
2016 Herbrink M, de Vries N, Rosing H, Huitema AD, Nuijen B, Schellens JH, Beijnen JH. Quantification of 11 Therapeutic Kinase Inhibitors in Human Plasma for Therapeutic Drug Monitoring Using Liquid Chromatography Coupled With Tandem Mass Spectrometry. Therapeutic Drug Monitoring. 38: 649-656. PMID 27749781 DOI: 10.1097/FTD.0000000000000349  1
2016 Sparidans RW, Rosing H, Rood JJ, Schellens JH, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the B-Raf inhibitor encorafenib, the EGFR inhibitors afatinib, erlotinib and gefitinib and the O-desmethyl metabolites of erlotinib and gefitinib in human plasma. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 1033: 390-398. PMID 27639128 DOI: 10.1016/j.jchromb.2016.09.012  1
2016 Meulendijks D, Cats A, Beijnen JH, Schellens JH. Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity - Ready for clinical practice? Cancer Treatment Reviews. 50: 23-34. PMID 27589829 DOI: 10.1016/j.ctrv.2016.08.002  0.84
2016 Lin F, de Gooijer MC, Hanekamp D, Chandrasekaran G, Buil L, Thota N, Sparidans RW, Beijnen JH, Wurdinger T, van Tellingen O. PI3K-mTOR pathway inhibition exhibits efficacy against high-grade glioma in clinically relevant mouse models. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27553832 DOI: 10.1158/1078-0432.CCR-16-1276  0.72
2016 Meulendijks D, Henricks LM, van Kuilenburg AB, Jacobs BA, Aliev A, Rozeman L, Meijer J, Beijnen JH, de Graaf H, Cats A, Schellens JH. Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines. Cancer Chemotherapy and Pharmacology. PMID 27544765 DOI: 10.1007/s00280-016-3137-0  0.84
2016 Yu H, van Erp N, Bins S, Mathijssen RH, Schellens JH, Beijnen JH, Steeghs N, Huitema AD. Development of a Pharmacokinetic Model to Describe the Complex Pharmacokinetics of Pazopanib in Cancer Patients. Clinical Pharmacokinetics. PMID 27534647 DOI: 10.1007/s40262-016-0443-y  0.84
2016 Sawicki E, Beijnen JH, Schellens JH, Nuijen B. Pharmaceutical development of an oral tablet formulation containing a spray dried amorphous solid dispersion of docetaxel or paclitaxel. International Journal of Pharmaceutics. PMID 27480397 DOI: 10.1016/j.ijpharm.2016.07.068  0.84
2016 Verheijen RB, Bins S, Mathijssen RH, Lolkema M, van Doorn L, Schellens JH, Beijnen JH, Langenberg MH, Huitema AD, Steeghs N. Individualized pazopanib dosing: a prospective feasibility study in cancer patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27470967 DOI: 10.1158/1078-0432.CCR-16-1255  0.84
2016 Rood JJ, van Bussel MT, Schellens JH, Beijnen JH, Sparidans RW. Liquid chromatography-tandem mass spectrometric assay for the T790M mutant EGFR inhibitor osimertinib (AZD9291) in human plasma. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 1031: 80-85. PMID 27469903 DOI: 10.1016/j.jchromb.2016.07.037  0.84
2016 Rood JJ, Schellens JH, Beijnen JH, Sparidans RW. Recent developments in the chromatographic bioanalysis of approved kinase inhibitor drugs in oncology. Journal of Pharmaceutical and Biomedical Analysis. PMID 27460293 DOI: 10.1016/j.jpba.2016.06.037  0.84
2016 van Brummelen EM, Ros W, Wolbink G, Beijnen JH, Schellens JH. Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges. The Oncologist. PMID 27440064 DOI: 10.1634/theoncologist.2016-0061  0.84
2016 Nijenhuis CM, Huitema AD, Blank C, Haanen JB, van Thienen JV, Rosing H, Schellens JH, Beijnen JH. Clinical Pharmacokinetics of Vemurafenib in BRAF-Mutated Melanoma Patients. Journal of Clinical Pharmacology. PMID 27365214 DOI: 10.1002/jcph.788  1
2016 Nijenhuis CM, Lucas L, Rosing H, Jamieson G, Fox JA, Schellens JH, Beijnen JH. Quantification of vosaroxin and its metabolites N-desmethylvosaroxin and O-desmethylvosaroxin in human plasma and urine using high-performance liquid chromatography-tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 1027: 1-10. PMID 27236532 DOI: 10.1016/j.jchromb.2016.05.016  1
2016 Nijenhuis CM, Hellriegel E, Beijnen JH, Hershock D, Huitema AD, Lucas L, Mergui-Roelvink M, Munteanu M, Rabinovich-Guilatt L, Robertson P, Rosing H, Spiegelstein O, Schellens JH. Pharmacokinetics and excretion of (14)C-omacetaxine in patients with advanced solid tumors. Investigational New Drugs. PMID 27221729 DOI: 10.1007/s10637-016-0360-9  1
2016 Sparidans RW, Kort A, Schinkel AH, Schellens JH, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for ponatinib and N-desmethyl ponatinib in mouse plasma. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 1023: 24-29. PMID 27179188 DOI: 10.1016/j.jchromb.2016.04.049  0.84
2016 Jacobs BA, Rosing H, de Vries N, Meulendijks D, Henricks LM, Schellens JH, Beijnen JH. Development and validation of a rapid and sensitive UPLC-MS/MS method for determination of uracil and dihydrouracil in human plasma. Journal of Pharmaceutical and Biomedical Analysis. 126: 75-82. PMID 27179185 DOI: 10.1016/j.jpba.2016.04.039  1
2016 Deenen MJ, Cats A, Severens JL, Beijnen JH, Schellens JH. Reply to T. Magnes et al. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 27161961 DOI: 10.1200/JCO.2016.67.4374  0.84
2016 Jacobs BA, Deenen MJ, Pluim D, van Hasselt JG, Krähenbühl MD, van Geel RM, de Vries N, Rosing H, Meulendijks D, Burylo AM, Cats A, Beijnen JH, Huitema AD, Schellens JH. Pronounced between-subject and circadian variability in thymidylate synthase and dihydropyrimidine dehydrogenase enzyme activity in human volunteers. British Journal of Clinical Pharmacology. PMID 27161955 DOI: 10.1111/bcp.13007  1
2016 Jacobs BA, Meulenaar J, Rosing H, Pluim D, Tibben MM, de Vries N, Nuijen B, Huitema AD, Beijnen JH, Schellens JH, Marchetti S. A phase 0 clinical trial of novel candidate extended-release formulations of capecitabine. Cancer Chemotherapy and Pharmacology. PMID 27103124 DOI: 10.1007/s00280-016-3035-5  1
2016 Dubbelman AC, Tibben M, Rosing H, Gebretensae A, Nan L, Gorman SH, Robertson P, Schellens JH, Beijnen JH. Corrigendum to "Development and validation of LC-MS/MS assays for the quantification of bendamustine and its metabolites in human plasma and urine" [J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 893-894 (2012) 92-100]. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 1020: 168-169. PMID 27063483 DOI: 10.1016/j.jchromb.2016.03.016  1
2016 Dubbelman AC, Nijenhuis CM, Jansen RS, Rosing H, Mizuo H, Kawaguchi S, Critchley D, Shumaker R, Schellens JH, Beijnen JH. Metabolite profiling of the multiple tyrosine kinase inhibitor lenvatinib: a cross-species comparison. Investigational New Drugs. PMID 27018262 DOI: 10.1007/s10637-016-0342-y  1
2016 Meulendijks D, de Groot JW, Los M, Boers JE, Beerepoot LV, Polee MB, Beeker A, Portielje JE, Goey SH, de Jong RS, Vanhoutvin SA, Kuiper M, Sikorska K, Pluim D, Beijnen JH, et al. Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: A multicenter phase 2 study. Cancer. PMID 26970343 DOI: 10.1002/cncr.29864  0.88
2016 van Brummelen EM, Huitema AD, van Werkhoven E, Beijnen JH, Schellens JH. The performance of model-based versus rule-based phase I clinical trials in oncology : A quantitative comparison of the performance of model-based versus rule-based phase I trials with molecularly targeted anticancer drugs over the last 2 years. Journal of Pharmacokinetics and Pharmacodynamics. PMID 26960536 DOI: 10.1007/s10928-016-9466-0  1
2016 Nijenhuis CM, Huitema AD, Marchetti S, Blank C, Haanen JB, van Thienen JV, Rosing H, Schellens JH, Beijnen JH. The use of Dried Blood Spots for Pharmacokinetic Monitoring of Vemurafenib Treatment in Melanoma Patients. Journal of Clinical Pharmacology. PMID 26918324 DOI: 10.1002/jcph.728  1
2016 de Vries Schultink AH, Suleiman AA, Schellens JH, Beijnen JH, Huitema AD. Pharmacodynamic modeling of adverse effects of anti-cancer drug treatment. European Journal of Clinical Pharmacology. PMID 26915815 DOI: 10.1007/s00228-016-2030-4  0.84
2016 de Groot MH, van Campen JP, Kosse NM, de Vries OJ, Beijnen JH, Lamoth CJ. The Association of Medication-Use and Frailty-Related Factors with Gait Performance in Older Patients. Plos One. 11: e0149888. PMID 26901048 DOI: 10.1371/journal.pone.0149888  1
2016 van Geel RM, Hendrikx JJ, Vahl JE, van Leerdam ME, van den Broek D, Huitema AD, Beijnen JH, Schellens JH, Burgers SA. Crizotinib-induced fatal fulminant liver failure. Lung Cancer (Amsterdam, Netherlands). 93: 17-9. PMID 26898609 DOI: 10.1016/j.lungcan.2015.12.010  1
2016 Sparidans RW, van Hoppe S, Rood JJ, Schinkel AH, Schellens JH, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for the tyrosine kinase inhibitor afatinib in mouse plasma using salting-out liquid-liquid extraction. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 1012: 118-123. PMID 26826475 DOI: 10.1016/j.jchromb.2016.01.025  1
2016 Meulendijks D, Henricks LM, Amstutz U, Froehlich TK, Largiadèr CR, Beijnen JH, de Boer A, Deenen MJ, Cats A, Schellens JH. Rs895819 in MIR27A improves the predictive value of DPYD variants to identify patients at risk of severe fluoropyrimidine-associated toxicity. International Journal of Cancer. Journal International Du Cancer. PMID 26804235 DOI: 10.1002/ijc.30014  0.84
2016 Kip AE, Rosing H, Hillebrand MJ, Blesson S, Mengesha B, Diro E, Hailu A, Schellens JH, Beijnen JH, Dorlo TP. Validation and clinical evaluation of a novel method to measure miltefosine in leishmaniasis patients using dried blood spot sample collection. Antimicrobial Agents and Chemotherapy. PMID 26787691 DOI: 10.1128/AAC.02976-15  1
2016 Meulendijks D, van Hasselt JG, Huitema AD, van Tinteren H, Deenen MJ, Beijnen JH, Cats A, Schellens JH. Renal function, body surface area, and age are associated with risk of early-onset fluoropyrimidine-associated toxicity in patients treated with capecitabine-based anticancer regimens in daily clinical care. European Journal of Cancer (Oxford, England : 1990). 54: 120-130. PMID 26761784 DOI: 10.1016/j.ejca.2015.10.013  0.88
2016 Crombag MR, Joerger M, Thürlimann B, Schellens JH, Beijnen JH, Huitema AD. Pharmacokinetics of Selected Anticancer Drugs in Elderly Cancer Patients: Focus on Breast Cancer. Cancers. 8. PMID 26729170 DOI: 10.3390/cancers8010006  1
2015 Derissen EJ, Jacobs BA, Huitema AD, Rosing H, Schellens JH, Beijnen JH. Exploring the intracellular pharmacokinetics of the 5-fluorouracil nucleotides during capecitabine treatment. British Journal of Clinical Pharmacology. PMID 26718616 DOI: 10.1111/bcp.12877  0.88
2015 Verheijen RB, Bins S, Thijssen B, Rosing H, Nan L, Schellens JH, Mathijssen RH, Lolkema MP, Beijnen JH, Steeghs N, Huitema AD. Development and clinical validation of an LC-MS/MS method for the quantification of pazopanib in DBS. Bioanalysis. PMID 26652864 DOI: 10.4155/bio.15.235  0.88
2015 Meulendijks D, Beerepoot LV, Boot H, de Groot JW, Los M, Boers JE, Vanhoutvin SA, Polee MB, Beeker A, Portielje JE, de Jong RS, Goey SH, Kuiper M, Sikorska K, Beijnen JH, et al. Trastuzumab and bevacizumab combined with docetaxel, oxaliplatin and capecitabine as first-line treatment of advanced HER2-positive gastric cancer: a multicenter phase II study. Investigational New Drugs. PMID 26643663 DOI: 10.1007/s10637-015-0309-4  1
2015 van Geel RM, Beijnen JH, Bernards R, Schellens JH. Treatment Individualization in Colorectal Cancer. Current Colorectal Cancer Reports. 11: 335-344. PMID 26617477 DOI: 10.1007/s11888-015-0288-z  1
2015 Meulendijks D, Henricks LM, Sonke GS, Deenen MJ, Froehlich TK, Amstutz U, Largiadèr CR, Jennings BA, Marinaki AM, Sanderson JD, Kleibl Z, Kleiblova P, Schwab M, Zanger UM, Palles C, ... ... Beijnen JH, et al. Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. The Lancet. Oncology. PMID 26603945 DOI: 10.1016/S1470-2045(15)00286-7  1
2015 Yu H, Hendrikx JJ, Rottenberg S, Schellens JH, Beijnen JH, Huitema AD. Development of a Tumour Growth Inhibition Model to Elucidate the Effects of Ritonavir on Intratumoural Metabolism and Anti-tumour Effect of Docetaxel in a Mouse Model for Hereditary Breast Cancer. The Aaps Journal. PMID 26603889 DOI: 10.1208/s12248-015-9838-1  0.88
2015 Deenen MJ, Meulendijks D, Cats A, Sechterberger MK, Severens JL, Boot H, Smits PH, Rosing H, Mandigers CM, Soesan M, Beijnen JH, Schellens JH. Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26573078 DOI: 10.1200/JCO.2015.63.1325  1
2015 Milojkovic Kerklaan B, Pluim D, Bol M, Hofland I, Westerga J, van Tinteren H, Beijnen JH, Boogerd W, Schellens JH, Brandsma D. EpCAM-based flow cytometry in cerebrospinal fluid greatly improves diagnostic accuracy of leptomeningeal metastases from epithelial tumors. Neuro-Oncology. PMID 26566655 DOI: 10.1093/neuonc/nov273  0.84
2015 Henricks LM, Schellens JH, Huitema AD, Beijnen JH. The use of combinations of monoclonal antibodies in clinical oncology. Cancer Treatment Reviews. PMID 26547132 DOI: 10.1016/j.ctrv.2015.10.008  1
2015 Rood JJ, van Hoppe S, Schinkel AH, Schellens JH, Beijnen JH, Sparidans RW. Liquid chromatography-tandem mass spectrometric assay for the simultaneous determination of the irreversible BTK inhibitor ibrutinib and its dihydrodiol-metabolite in plasma and its application in mouse pharmacokinetic studies. Journal of Pharmaceutical and Biomedical Analysis. 118: 123-131. PMID 26540627 DOI: 10.1016/j.jpba.2015.10.033  0.88
2015 Keusters WR, Frederix GW, de Weger VA, Beijnen JH, Hövels AM, Schellens JH. Decrease of Patient Costs in the Netherlands: a Cost of Illness Study in Metastatic Non Small Cell Lung Cancer (Nsclc). Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 18: A446. PMID 26532512 DOI: 10.1016/j.jval.2015.09.1113  0.84
2015 Deenen MJ, Meulendijks D, Boot H, Legdeur MJ, Beijnen JH, Schellens JH, Cats A. Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction. Cancer Chemotherapy and Pharmacology. PMID 26499900 DOI: 10.1007/s00280-015-2872-y  0.88
2015 Milojkovic Kerklaan B, van Tellingen O, Huitema AD, Beijnen JH, Boogerd W, Schellens JH, Brandsma D. Strategies to target drugs to gliomas and CNS metastases of solid tumors. Journal of Neurology. PMID 26477024 DOI: 10.1007/s00415-015-7919-9  1
2015 van der Noll R, Smit WM, Wymenga AN, Boss DS, Grob M, Huitema AD, Rosing H, Tibben MM, Keessen M, Rehorst H, Beijnen JH, Schellens JH. Phase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancer. Investigational New Drugs. PMID 26362459 DOI: 10.1007/s10637-015-0281-z  0.88
2015 Kort A, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH. Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2). Pharmacological Research. PMID 26361725 DOI: 10.1016/j.phrs.2015.09.003  1
2015 Nijenhuis CM, Lucas L, Rosing H, Schellens JH, Beijnen JH, Gorman SH, Burke SM, Campbell DA, Chapple MW, Yousey TH, Mulvana DE. Validation of high-performance liquid chromatography-tandem mass spectrometry assays quantifying omacetaxine mepesuccinate and its 4'‑des-methyl and cephalotaxine metabolites in human plasma and urine. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 1002: 152-9. PMID 26319804 DOI: 10.1016/j.jchromb.2015.08.015  1
2015 Tang SC, Kort A, Cheung KL, Rosing H, Fukami T, Durmus S, Wagenaar E, Hendrikx JJ, Nakajima M, van Vlijmen BJ, Beijnen JH, Schinkel AH. P-glycoprotein, CYP3A, and Plasma Carboxylesterase Determine Brain Disposition and Oral Availability of the Novel Taxane Cabazitaxel (Jevtana) in Mice. Molecular Pharmaceutics. PMID 26317243 DOI: 10.1021/acs.molpharmaceut.5b00470  1
2015 van Hasselt J, Gupta A, Hussein Z, Beijnen JH, Schellens J, Huitema A. Disease Progression/Clinical Outcome Model for Castration-Resistant Prostate Cancer in Patients Treated With Eribulin. Cpt: Pharmacometrics & Systems Pharmacology. 4: 386-95. PMID 26312162 DOI: 10.1002/psp4.49  0.52
2015 van Hasselt J, Gupta A, Hussein Z, Beijnen JH, Schellens J, Huitema A. Integrated Simulation Framework for Toxicity, Dose Intensity, Disease Progression, and Cost Effectiveness for Castration-Resistant Prostate Cancer Treatment With Eribulin. Cpt: Pharmacometrics & Systems Pharmacology. 4: 374-85. PMID 26312161 DOI: 10.1002/psp4.48  0.52
2015 Wouters H, Van Campen JP, Appels BA, Beijnen JH, Zwinderman AH, Van Gool WA, Schmand B. Individualized evaluation of cholinesterase inhibitors effects in dementia with adaptive cognitive testing. International Journal of Methods in Psychiatric Research. PMID 26299847 DOI: 10.1002/mpr.1484  1
2015 Hendrikx JJ, Lagas JS, Song JY, Rosing H, Schellens JH, Beijnen JH, Rottenberg S, Schinkel AH. Ritonavir inhibits intratumoral docetaxel metabolism and enhances docetaxel antitumor activity in an immunocompetent mouse breast cancer model. International Journal of Cancer. Journal International Du Cancer. PMID 26297509 DOI: 10.1002/ijc.29812  0.88
2015 Meulendijks D, Jacobs BA, Aliev A, Pluim D, van Werkhoven E, Deenen MJ, Beijnen JH, Cats A, Schellens JH. Increased risk of severe fluoropyrimidine-associated toxicity in patients carrying a G>C Substitution in the First 28-bp tandem repeat of the thymidylate synthase 2R Allele. International Journal of Cancer. Journal International Du Cancer. PMID 26189437 DOI: 10.1002/ijc.29694  0.88
2015 van der Noll R, Marchetti S, Steeghs N, Beijnen JH, Mergui-Roelvink MW, Harms E, Rehorst H, Sonke GS, Schellens JH. Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer. British Journal of Cancer. 113: 396-402. PMID 26180927 DOI: 10.1038/bjc.2015.256  0.84
2015 Kip AE, Rosing H, Hillebrand MJ, Castro MM, Gomez MA, Schellens JH, Beijnen JH, Dorlo TP. Quantification of miltefosine in peripheral blood mononuclear cells by high-performance liquid chromatography-tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 998: 57-62. PMID 26160472 DOI: 10.1016/j.jchromb.2015.06.017  1
2015 de Gooijer MC, Zhang P, Thota N, Mayayo-Peralta I, Buil LC, Beijnen JH, van Tellingen O. P-glycoprotein and breast cancer resistance protein restrict the brain penetration of the CDK4/6 inhibitor palbociclib. Investigational New Drugs. 33: 1012-9. PMID 26123925 DOI: 10.1007/s10637-015-0266-y  0.52
2015 Keizer RJ, Jansen RS, Rosing H, Thijssen B, Beijnen JH, Schellens JH, Huitema AD. Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses. Pharmacology Research & Perspectives. 3: e00131. PMID 26038706 DOI: 10.1002/prp2.131  1
2015 Jager NG, Rosing H, Linn SC, Schellens JH, Beijnen JH. Dried blood spot self-sampling at home for the individualization of tamoxifen treatment: a feasibility study. Therapeutic Drug Monitoring. PMID 26035041 DOI: 10.1097/FTD.0000000000000224  0.88
2015 Jager NG, Linn SC, Schellens JH, Beijnen JH. Tailored Tamoxifen Treatment for Breast Cancer Patients: A Perspective. Clinical Breast Cancer. PMID 25997856 DOI: 10.1016/j.clbc.2015.04.005  0.88
2015 de Vries Schultink AH, Zwart W, Linn SC, Beijnen JH, Huitema AD. Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen. Clinical Pharmacokinetics. 54: 797-810. PMID 25940823 DOI: 10.1007/s40262-015-0273-3  0.8
2015 van Hasselt JG, Allegaert K, van Calsteren K, Beijnen JH, Schellens JH, Huitema AD. Corrigendum to "Semiphysiological versus Empirical Modelling of the Population Pharmacokinetics of Free and Total Cefazolin during Pregnancy". Biomed Research International. 2015: 124035. PMID 25922829 DOI: 10.1155/2015/124035  0.84
2015 Meulendijks D, Tomasoa NB, Dewit L, Smits PH, Bakker R, van Velthuysen ML, Rosenberg EH, Beijnen JH, Schellens JH, Cats A. HPV-negative squamous cell carcinoma of the anal canal is unresponsive to standard treatment and frequently carries disruptive mutations in TP53. British Journal of Cancer. 112: 1358-66. PMID 25871546 DOI: 10.1038/bjc.2015.20  1
2015 Zhang P, de Gooijer MC, Buil LC, Beijnen JH, Li G, van Tellingen O. ABCB1 and ABCG2 restrict the brain penetration of a panel of novel EZH2-Inhibitors. International Journal of Cancer. Journal International Du Cancer. PMID 25868794 DOI: 10.1002/ijc.29566  1
2015 Pluim D, Jacobs BA, Deenen MJ, Ruijter AE, van Geel RM, Burylo AM, Meulendijks D, Beijnen JH, Schellens JH. Improved pharmacodynamic assay for dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells. Bioanalysis. 7: 519-29. PMID 25826134 DOI: 10.4155/bio.14.304  1
2015 Herbrink M, Nuijen B, Schellens JH, Beijnen JH. Variability in bioavailability of small molecular tyrosine kinase inhibitors. Cancer Treatment Reviews. 41: 412-422. PMID 25818541 DOI: 10.1016/j.ctrv.2015.03.005  1
2015 Derissen EJ, Hillebrand MJ, Rosing H, Schellens JH, Beijnen JH. Development of an LC-MS/MS assay for the quantitative determination of the intracellular 5-fluorouracil nucleotides responsible for the anticancer effect of 5-fluorouracil. Journal of Pharmaceutical and Biomedical Analysis. 110: 58-66. PMID 25804433 DOI: 10.1016/j.jpba.2015.02.051  0.88
2015 Vogel CJ, Smit MA, Maddalo G, Possik PA, Sparidans RW, van der Burg SH, Verdegaal EM, Heck AJ, Samatar AA, Beijnen JH, Altelaar AF, Peeper DS. Cooperative induction of apoptosis in NRAS mutant melanoma by inhibition of MEK and ROCK. Pigment Cell & Melanoma Research. 28: 307-17. PMID 25728708 DOI: 10.1111/pcmr.12364  1
2015 Lankheet NA, Schaake EE, Burgers SA, van Pel R, Beijnen JH, Huitema AD, Klomp H. Concentrations of Erlotinib in Tumor Tissue and Plasma in Non-Small-Cell Lung Cancer Patients After Neoadjuvant Therapy. Clinical Lung Cancer. 16: 320-4. PMID 25682545 DOI: 10.1016/j.cllc.2014.12.012  0.72
2015 Joerger M, Huitema AD, Boot H, Cats A, Doodeman VD, Smits PH, Vainchtein L, Rosing H, Meijerman I, Zueger M, Meulendijks D, Cerny TD, Beijnen JH, Schellens JH. Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy. Cancer Chemotherapy and Pharmacology. 75: 763-72. PMID 25677447 DOI: 10.1007/s00280-015-2698-7  1
2015 Devriese LA, Witteveen PE, Mergui-Roelvink M, Smith DA, Lewis LD, Mendelson DS, Bang YJ, Chung HC, Dar MM, Huitema AD, Beijnen JH, Voest EE, Schellens JH. Pharmacodynamics and pharmacokinetics of oral topotecan in patients with advanced solid tumours and impaired renal function. British Journal of Clinical Pharmacology. PMID 25677219 DOI: 10.1111/bcp.12606  1
2015 Dolman ME, Westerhout EM, Hamdi M, Schellens JH, Beijnen JH, Sparidans RW. Liquid chromatography-tandem mass spectrometric assay for the PI3K/mTOR inhibitor GSK2126458 in mouse plasma and tumor homogenate. Journal of Pharmaceutical and Biomedical Analysis. 107: 403-8. PMID 25659532 DOI: 10.1016/j.jpba.2015.01.026  1
2015 Meulendijks D, Khan S, Koks CH, Huitema AD, Schellens JH, Beijnen JH. Baclofen overdose treated with continuous venovenous hemofiltration. European Journal of Clinical Pharmacology. 71: 357-61. PMID 25567218 DOI: 10.1007/s00228-014-1802-y  1
2015 Kort A, Durmus S, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH. Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1). Pharmaceutical Research. 32: 2205-16. PMID 25563977 DOI: 10.1007/s11095-014-1609-7  0.76
2015 Mehta AM, Van den Hoven JM, Rosing H, Hillebrand MJ, Nuijen B, Huitema AD, Beijnen JH, Verwaal VJ. Stability of oxaliplatin in chloride-containing carrier solutions used in hyperthermic intraperitoneal chemotherapy. International Journal of Pharmaceutics. 479: 23-7. PMID 25535649 DOI: 10.1016/j.ijpharm.2014.12.025  1
2015 Yu H, Steeghs N, Kloth JS, de Wit D, van Hasselt JG, van Erp NP, Beijnen JH, Schellens JH, Mathijssen RH, Huitema AD. Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662. British Journal of Clinical Pharmacology. 79: 809-19. PMID 25393890 DOI: 10.1111/bcp.12550  0.88
2015 Dubbelman AC, Rosing H, Nijenhuis C, Huitema AD, Mergui-Roelvink M, Gupta A, Verbel D, Thompson G, Shumaker R, Schellens JH, Beijnen JH. Pharmacokinetics and excretion of (14)C-lenvatinib in patients with advanced solid tumors or lymphomas. Investigational New Drugs. 33: 233-40. PMID 25377392 DOI: 10.1007/s10637-014-0181-7  1
2015 Kip AE, Balasegaram M, Beijnen JH, Schellens JH, de Vries PJ, Dorlo TP. Systematic review of biomarkers to monitor therapeutic response in leishmaniasis. Antimicrobial Agents and Chemotherapy. 59: 1-14. PMID 25367913 DOI: 10.1128/AAC.04298-14  0.88
2015 Leijen S, Burgers SA, Baas P, Pluim D, Tibben M, van Werkhoven E, Alessio E, Sava G, Beijnen JH, Schellens JH. Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy. Investigational New Drugs. 33: 201-14. PMID 25344453 DOI: 10.1007/s10637-014-0179-1  1
2015 Durmus S, Sparidans RW, van Esch A, Wagenaar E, Beijnen JH, Schinkel AH. Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) restrict oral availability and brain accumulation of the PARP inhibitor rucaparib (AG-014699). Pharmaceutical Research. 32: 37-46. PMID 24962512 DOI: 10.1007/s11095-014-1442-z  0.76
2015 Iusuf D, Hendrikx JJMA, van Esch A, van de Steeg E, Wagenaar E, Rosing H, Beijnen JH, Schinkel AH. Human OATP1B1, OATP1B3 and OATP1A2 can mediate the in vivo uptake and clearance of docetaxel International Journal of Cancer. Journal International Du Cancer. 136: 225-233. PMID 24825069 DOI: 10.1002/ijc.28970  1
2015 Janssens T, Brouwers EE, de Vos JP, de Vries N, Schellens JH, Beijnen JH. Inductively coupled plasma mass-spectrometric determination of platinum in excretion products of client-owned pet dogs. Veterinary and Comparative Oncology. 13: 124-32. PMID 23714139 DOI: 10.1111/vco.12025  1
2015 Aarts F, Radhakishun NNE, Van Vliet M, Geenen R, Von Rosenstiel IA, Hinnen C, Beijnen JH, Brandjes DPM, Diamant M, Gerdes VEA. Gastric bypass may promote weight loss in overweight partners Journal of the American Board of Family Medicine. 28: 90-96. DOI: 10.3122/jabfm.2015.01.140103  0.6
2015 van der Noll R, Marchetti S, Steeghs N, Beijnen JH, Mergui-Roelvink MWJ, Harms E, Rehorst H, Sonke GS, Schellens JHM. Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer British Journal of Cancer. DOI: 10.1038/bjc.2015.256  1
2015 Kip AE, Rosing H, Hillebrand MJX, Castro MM, Gomez MA, Schellens JHM, Beijnen JH, Dorlo TPC. Quantification of miltefosine in peripheral blood mononuclear cells by high-performance liquid chromatography-tandem mass spectrometry Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences. 998: 57-62. DOI: 10.1016/j.jchromb.2015.06.017  1
2015 Mehta AM, Van Den Hoven JM, Rosing H, Hillebrand MJX, Nuijen B, Huitema ADR, Beijnen JH, Verwaal VJ. Stability of oxaliplatin in chloride-containing carrier solutions used in hyperthermic intraperitoneal chemotherapy International Journal of Pharmaceutics. 479: 23-27. DOI: 10.1016/j.ijpharm.2014.12.025  0.56
2015 Lankheet NAG, Schaake EE, Burgers SA, Van Pel R, Beijnen JH, Huitema ADR, Klomp H. Concentrations of erlotinib in tumor tissue and plasma in non-small-cell lung cancer patients after neoadjuvant therapy Clinical Lung Cancer. 16: 320-324. DOI: 10.1016/j.cllc.2014.12.012  1
2015 de Vries Schultink AHM, Zwart W, Linn SC, Beijnen JH, Huitema ADR. Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen Clinical Pharmacokinetics. 54: 797-810. DOI: 10.1007/s40262-015-0273-3  1
2015 Kort A, Durmus S, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH. Brain and testis accumulation of regorafenib is restricted by breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) Pharmaceutical Research. 32: 2205-2216. DOI: 10.1007/s11095-014-1609-7  1
2015 de Gooijer MC, Zhang P, Thota N, Mayayo-Peralta I, Buil LCM, Beijnen JH, van Tellingen O. P-glycoprotein and breast cancer resistance protein restrict the brain penetration of the CDK4/6 inhibitor palbociclib Investigational New Drugs. DOI: 10.1007/s10637-015-0266-y  1
2015 Van Hasselt JGC, Gupta A, Hussein Z, Beijnen JH, Schellens JHM, Huitema ADR. Disease Progression/Clinical Outcome Model for Castration-Resistant Prostate Cancer in Patients Treated with Eribulin Cpt: Pharmacometrics and Systems Pharmacology. 4: 386-395. DOI: 10.1002/psp4.49  1
2015 Van Hasselt JGC, Gupta A, Hussein Z, Beijnen JH, Schellens JHM, Huitema ADR. Integrated Simulation Framework for Toxicity, Dose Intensity, Disease Progression, and Cost Effectiveness for Castration-Resistant Prostate Cancer Treatment with Eribulin Cpt: Pharmacometrics and Systems Pharmacology. 4: 374-385. DOI: 10.1002/psp4.48  1
2015 Dorlo TPC, Balasegaram M, Beijnen JH, De Vries PJ, Huitema ADR. Translational pharmacokinetic modelling and simulation for the assessment of duration of contraceptive use after treatment with miltefosine | Translationele farmacokinetische modellering en simulatie om de duur van anticonceptie te bepalen na behandeling met miltefosine Pharmaceutisch Weekblad. 150: 94-101.  0.88
2015 Henricks LM, Schellens JHM, Beijnen JH, Huitema ADR. Combined application of monoclonal antibodies in oncology | Gecombineerde toepassing van monoklonale antilichamen in de oncologie Pharmaceutisch Weekblad. 150: 46-53.  1
2015 Geenen JJ, Linn SC, Beijnen JH, Schellens JHM. Olaparib: Antineoplastic agent with a unique mechanism of action | Olaparib: Oncolyticum met uniek werkingsmechanisme Pharmaceutisch Weekblad. 150: 10-11.  1
2015 Hendrikx JJMA, Lagas JS, Wagenaar E, Rosing H, Schellens JHM, Beijnen JH, Schinkel AH. Oral co-administration of elacridar and ritonavir enhances plasma levels of oral paclitaxel and docetaxel without affecting relative brain accumulation | Remming van P-glycoproteyne en cytochroom P450 3A verhoogt de absorptie, maar niet de hersenpenetratie van oraal toegediende taxanen Pharmaceutisch Weekblad. 150: 165-172.  0.88
2014 Joerger M, Huitema AD, Boot H, Cats A, Doodeman V, Smits P, Vainchtein L, Rosing H, Meijerman I, Zueger M, Cerny TT, Beijnen JH, Schellens J. 1577PGERMLINE TYMS GENOTYPE IS HIGHLY PREDICTIVE IN PATIENTS WITH ADVANCED COLORECTAL AND GASTROESOPHAGEAL CANCER INDEPENDENT OF FLUOROPYRIMIDINE PHARMACOLOGY: RESULTS FROM TWO PROSPECTIVE TRANSLATIONAL STUDIES. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv548. PMID 28172174 DOI: 10.1093/annonc/mdu358.8  1
2014 Hendrikx JJ, Beijnen JH, Schinkel AH. P-gp and taxanes. Oncoscience. 1: 478-9. PMID 25594047 DOI: 10.18632/oncoscience.56  1
2014 Nijenhuis CM, Rosing H, Schellens JH, Beijnen JH. Quantifying vemurafenib in dried blood spots using high-performance LC-MS/MS. Bioanalysis. 6: 3215-24. PMID 25529888 DOI: 10.4155/bio.14.171  1
2014 Jager NG, Rosing H, Schellens JH, Beijnen JH. Determination of tamoxifen and endoxifen in dried blood spots using LC-MS/MS and the effect of coated DBS cards on recovery and matrix effects. Bioanalysis. 6: 2999-3009. PMID 25496254 DOI: 10.4155/bio.14.157  1
2014 Houthuijzen JM, Daenen LG, Roodhart JM, Oosterom I, van Jaarsveld MT, Govaert KM, Smith ME, Sadatmand SJ, Rosing H, Kruse F, Helms BJ, van Rooijen N, Beijnen JH, Haribabu B, van de Lest CH, et al. Lysophospholipids secreted by splenic macrophages induce chemotherapy resistance via interference with the DNA damage response. Nature Communications. 5: 5275. PMID 25387467 DOI: 10.1038/ncomms6275  1
2014 Jager NG, Rosing H, Schellens JH, Beijnen JH. Procedures and practices for the validation of bioanalytical methods using dried blood spots: a review. Bioanalysis. 6: 2481-514. PMID 25384597 DOI: 10.4155/bio.14.185  1
2014 Crombag MR, de Vries Schultink AH, Schellens JH, Beijnen JH, Huitema AD. Incidence of hematologic toxicity in older adults treated with gemcitabine or a gemcitabine-containing regimen in routine clinical practice: a multicenter retrospective cohort study. Drugs & Aging. 31: 737-47. PMID 25216600 DOI: 10.1007/s40266-014-0207-z  1
2014 van Hasselt JG, van Eijkelenburg NK, Beijnen JH, Schellens JH, Huitema AD. Design of a drug-drug interaction study of vincristine with azole antifungals in pediatric cancer patients using clinical trial simulation. Pediatric Blood & Cancer. 61: 2223-9. PMID 25175364 DOI: 10.1002/pbc.25198  1
2014 Meulendijks D, Dewit L, Tomasoa NB, van Tinteren H, Beijnen JH, Schellens JH, Cats A. Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option. British Journal of Cancer. 111: 1726-33. PMID 25167226 DOI: 10.1038/bjc.2014.467  1
2014 Gomez-Eerland R, Nuijen B, Heemskerk B, van Rooij N, van den Berg JH, Beijnen JH, Uckert W, Kvistborg P, Schumacher TN, Haanen JB, Jorritsma A. Manufacture of gene-modified human T-cells with a memory stem/central memory phenotype. Human Gene Therapy Methods. 25: 277-87. PMID 25143008 DOI: 10.1089/hgtb.2014.004  1
2014 Opdam FL, Huitema AD, Beijnen JH, Schellens JH. [Hyperglycaemia during treatment with everolimus]. Nederlands Tijdschrift Voor Geneeskunde. 158: A7544. PMID 25115206  1
2014 Marchetti S, Pluim D, Beijnen JH, Mazzanti R, van Tellingen O, Schellens JH. "Effect of the drug transporters ABCB1, ABCC2, and ABCG2 on the disposition and brain accumulation of the taxane analog BMS-275,183". Investigational New Drugs. 32: 1083-95. PMID 25078948 DOI: 10.1007/s10637-014-0143-0  1
2014 Radhakishun NN, van Vliet M, Poland DC, Weijer O, Beijnen JH, Brandjes DP, Diamant M, von Rosenstiel IA. Efficacy and tolerability of a high loading dose (25,000 IU weekly) vitamin D3 supplementation in obese children with vitamin D insufficiency/deficiency. Hormone Research in PæDiatrics. 82: 103-6. PMID 25060306 DOI: 10.1159/000362236  1
2014 Radhakishun N, van Vliet M, von Rosenstiel I, Weijer O, Diamant M, Beijnen J, Brandjes D. High prevalence of vitamin D insufficiency/deficiency in Dutch multi-ethnic obese children European Journal of Pediatrics. 174: 183-190. PMID 25015716 DOI: 10.1007/s00431-014-2378-3  1
2014 Widmer N, Bardin C, Chatelut E, Paci A, Beijnen J, Levêque D, Veal G, Astier A. Review of therapeutic drug monitoring of anticancer drugs part two - Targeted therapies European Journal of Cancer. 50: 2020-2036. PMID 24928190 DOI: 10.1016/j.ejca.2014.04.015  1
2014 Paci A, Veal G, Bardin C, Levêque D, Widmer N, Beijnen J, Astier A, Chatelut E. Review of therapeutic drug monitoring of anticancer drugs part 1 - Cytotoxics European Journal of Cancer. 50: 2010-2019. PMID 24889915 DOI: 10.1016/j.ejca.2014.04.014  1
2014 Bardin C, Veal G, Paci A, Chatelut E, Astier A, Levêque D, Widmer N, Beijnen J. Therapeutic drug monitoring in cancer - Are we missing a trick? European Journal of Cancer. 50: 2005-2009. PMID 24878063 DOI: 10.1016/j.ejca.2014.04.013  1
2014 Jager NG, Rosing H, Schellens JH, Beijnen JH, Linn SC. Use of dried blood spots for the determination of serum concentrations of tamoxifen and endoxifen. Breast Cancer Research and Treatment. 146: 137-44. PMID 24859000 DOI: 10.1007/s10549-014-2999-2  1
2014 Hendrikx JJ, Rosing H, Schinkel AH, Schellens JH, Beijnen JH. Quantification of taxanes in biological matrices: a review of bioanalytical assays and recommendations for development of new assays. Bioanalysis. 6: 993-1010. PMID 24806907 DOI: 10.4155/bio.14.48  1
2014 van Hasselt JG, Schellens JH, Beijnen JH, Huitema AD. Design of informative renal impairment studies: evaluation of the impact of design stratification on bias, precision and dose adjustment error. Investigational New Drugs. 32: 913-27. PMID 24788562 DOI: 10.1007/s10637-014-0103-8  1
2014 Hendrikx JJ, Lagas JS, Wagenaar E, Rosing H, Schellens JH, Beijnen JH, Schinkel AH. Oral co-administration of elacridar and ritonavir enhances plasma levels of oral paclitaxel and docetaxel without affecting relative brain accumulation. British Journal of Cancer. 110: 2669-76. PMID 24781280 DOI: 10.1038/bjc.2014.222  1
2014 Lankheet NA, Kloth JS, Gadellaa-van Hooijdonk CG, Cirkel GA, Mathijssen RH, Lolkema MP, Schellens JH, Voest EE, Sleijfer S, de Jonge MJ, Haanen JB, Beijnen JH, Huitema AD, Steeghs N. Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours. British Journal of Cancer. 110: 2441-9. PMID 24736581 DOI: 10.1038/bjc.2014.194  1
2014 Mooiman KD, Goey AK, Huijbregts TJ, Maas-Bakker RF, Beijnen JH, Schellens JH, Meijerman I. The in-vitro effect of complementary and alternative medicines on cytochrome P450 2C9 activity. The Journal of Pharmacy and Pharmacology. 66: 1339-46. PMID 24730468 DOI: 10.1111/jphp.12259  1
2014 Tang SC, Sparidans RW, Cheung KL, Fukami T, Durmus S, Wagenaar E, Yokoi T, van Vlijmen BJ, Beijnen JH, Schinkel AH. P-glycoprotein, CYP3A, and plasma carboxylesterase determine brain and blood disposition of the mTOR Inhibitor everolimus (Afinitor) in mice. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 3133-45. PMID 24727322 DOI: 10.1158/1078-0432.CCR-13-1759  0.76
2014 Hendrikx JJ, Lagas JS, Daling R, Hooijberg JH, Schellens JH, Beijnen JH, Brandjes DP, Huitema AD. Severe lactic acidosis in a diabetic patient after ethanol abuse and floor cleaner intake. Basic & Clinical Pharmacology & Toxicology. 115: 472-5. PMID 24717115 DOI: 10.1111/bcpt.12251  1
2014 van Hasselt JG, van Calsteren K, Heyns L, Han S, Mhallem Gziri M, Schellens JH, Beijnen JH, Huitema AD, Amant F. Optimizing anticancer drug treatment in pregnant cancer patients: pharmacokinetic analysis of gestation-induced changes for doxorubicin, epirubicin, docetaxel and paclitaxel. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 25: 2059-65. PMID 24713311 DOI: 10.1093/annonc/mdu140  1
2014 ter Heine R, Binkhorst L, de Graan AJ, de Bruijn P, Beijnen JH, Mathijssen RH, Huitema AD. Population pharmacokinetic modelling to assess the impact of CYP2D6 and CYP3A metabolic phenotypes on the pharmacokinetics of tamoxifen and endoxifen. British Journal of Clinical Pharmacology. 78: 572-86. PMID 24697814 DOI: 10.1111/bcp.12388  0.72
2014 van Hasselt JG, Allegaert K, van Calsteren K, Beijnen JH, Schellens JH, Huitema AD. Semiphysiological versus empirical modelling of the population pharmacokinetics of free and total cefazolin during pregnancy. Biomed Research International. 2014: 897216. PMID 24672799 DOI: 10.1155/2014/897216  1
2014 Lin F, De Gooijer MC, Roig EM, Buil LCM, Christner SM, Beumer JH, WEurdinger T, Beijnen JH, Van Tellingen O. ABCB1, ABCG2, and PTEN determine the response of glioblastoma to temozolomide and ABT-888 therapy Clinical Cancer Research. 20: 2703-2713. PMID 24647572 DOI: 10.1158/1078-0432.CCR-14-0084  1
2014 Goey AK, Beijnen JH, Schellens JH. Herb-drug interactions in oncology. Clinical Pharmacology and Therapeutics. 95: 354-5. PMID 24646483 DOI: 10.1038/clpt.2014.18  1
2014 de Weger VA, Beijnen JH, Schellens JH. Cellular and clinical pharmacology of the taxanes docetaxel and paclitaxel--a review. Anti-Cancer Drugs. 25: 488-94. PMID 24637579 DOI: 10.1097/CAD.0000000000000093  1
2014 Luethi D, Durmus S, Schinkel AH, Schellens JH, Beijnen JH, Sparidans RW. Liquid chromatography-tandem mass spectrometric assay for the multikinase inhibitor regorafenib in plasma. Biomedical Chromatography : Bmc. 28: 1366-70. PMID 24619951 DOI: 10.1002/bmc.3176  1
2014 Yu H, Steeghs N, Nijenhuis CM, Schellens JH, Beijnen JH, Huitema AD. Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets. Clinical Pharmacokinetics. 53: 305-25. PMID 24566736 DOI: 10.1007/s40262-014-0137-2  1
2014 Radhakishun N, Blokhuis C, Van Vliet M, Von Rosenstiel I, Weijer O, Heymans M, Beijnen J, Brandjes D, Diamant M. Intermittent fasting during Ramadan causes a transient increase in total, LDL, and HDL cholesterols and hs-CRP in ethnic obese adolescents European Journal of Pediatrics. 173: 1103-1106. PMID 24522324 DOI: 10.1007/s00431-014-2276-8  1
2014 Dolman ME, den Hartog IJ, Molenaar JJ, Schellens JH, Beijnen JH, Sparidans RW. Liquid chromatography-tandem mass spectrometric assay for the light sensitive survivin suppressant sepantronium bromide (YM155) in mouse plasma. Journal of Pharmaceutical and Biomedical Analysis. 92: 144-8. PMID 24518133 DOI: 10.1016/j.jpba.2014.01.011  1
2014 Dorlo TPC, Rijal S, Ostyn B, De Vries PJ, Singh R, Bhattarai N, Uranw S, Dujardin JC, Boelaert M, Beijnen JH, Huitema ADR. Failure of miltefosine in visceral leishmaniasis is associated with low drug exposure Journal of Infectious Diseases. 210: 146-153. PMID 24443541 DOI: 10.1093/infdis/jiu039  1
2014 Mooiman KD, Maas-Bakker RF, Hendrikx JJ, Bank PC, Rosing H, Beijnen JH, Schellens JH, Meijerman I. The effect of complementary and alternative medicines on CYP3A4-mediated metabolism of three different substrates: 7-benzyloxy-4-trifluoromethyl-coumarin, midazolam and docetaxel. The Journal of Pharmacy and Pharmacology. 66: 865-74. PMID 24392691 DOI: 10.1111/jphp.12208  1
2014 Jager NG, Rosing H, Schellens JH, Linn SC, Beijnen JH. Tamoxifen dose and serum concentrations of tamoxifen and six of its metabolites in routine clinical outpatient care. Breast Cancer Research and Treatment. 143: 477-83. PMID 24390246 DOI: 10.1007/s10549-013-2826-1  1
2014 Vlaming ML, Teunissen SF, van de Steeg E, van Esch A, Wagenaar E, Brunsveld L, de Greef TF, Rosing H, Schellens JH, Beijnen JH, Schinkel AH. Bcrp1;Mdr1a/b;Mrp2 combination knockout mice: altered disposition of the dietary carcinogen PhIP (2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine) and its genotoxic metabolites. Molecular Pharmacology. 85: 520-30. PMID 24334255 DOI: 10.1124/mol.113.088823  1
2014 Derissen EJ, Hillebrand MJ, Rosing H, Otten HM, Laille E, Schellens JH, Beijnen JH. Quantitative determination of azacitidine triphosphate in peripheral blood mononuclear cells using liquid chromatography coupled with high-resolution mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis. 90: 7-14. PMID 24317024 DOI: 10.1016/j.jpba.2013.11.010  1
2014 Meulenaar J, Keizer RJ, Beijnen JH, Schellens JH, Huitema AD, Nuijen B. Development of an extended-release formulation of capecitabine making use of in vitro-in vivo correlation modelling. Journal of Pharmaceutical Sciences. 103: 478-84. PMID 24311366 DOI: 10.1002/jps.23779  1
2014 Lankheet NA, Knapen LM, Schellens JH, Beijnen JH, Steeghs N, Huitema AD. Plasma concentrations of tyrosine kinase inhibitors imatinib, erlotinib, and sunitinib in routine clinical outpatient cancer care. Therapeutic Drug Monitoring. 36: 326-34. PMID 24305627 DOI: 10.1097/FTD.0000000000000004  1
2014 de Groot MH, van der Jagt-Willems HC, van Campen JP, Lems WF, Beijnen JH, Lamoth CJ. A flexed posture in elderly patients is associated with impairments in postural control during walking. Gait & Posture. 39: 767-72. PMID 24268470 DOI: 10.1016/j.gaitpost.2013.10.015  1
2014 Helgason HH, Koolen SL, Werkhoven Ev, Malingre MM, Kruijtzer CM, Huitema AD, Schot ME, Smit WM, Beijnen JH, Schellens JH. Phase II and pharmacological study of oral docetaxel plus cyclosporin A in anthracycline pre-treated metastatic breast cancer. Current Clinical Pharmacology. 9: 139-47. PMID 24219005 DOI: 10.2174/1574884708666131111193403  1
2014 Nijenhuis CM, Rosing H, Schellens JH, Beijnen JH. Development and validation of a high-performance liquid chromatography-tandem mass spectrometry assay quantifying vemurafenib in human plasma. Journal of Pharmaceutical and Biomedical Analysis. 88: 630-5. PMID 24216282 DOI: 10.1016/j.jpba.2013.10.019  1
2014 Sparidans RW, Durmus S, Schinkel AH, Schellens JH, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for the PARP inhibitor rucaparib in plasma. Journal of Pharmaceutical and Biomedical Analysis. 88: 626-9. PMID 24216281 DOI: 10.1016/j.jpba.2013.10.016  1
2014 Joerger M, Huitema AD, Koeberle D, Rosing H, Beijnen JH, Hitz F, Cerny T, Schellens JH, Gillessen S. Safety and pharmacology of gemcitabine and capecitabine in patients with advanced pancreatico-biliary cancer and hepatic dysfunction. Cancer Chemotherapy and Pharmacology. 73: 113-24. PMID 24166106 DOI: 10.1007/s00280-013-2327-2  1
2014 Dolman ME, den Hartog IJ, Molenaar JJ, Schellens JH, Beijnen JH, Sparidans RW. Liquid chromatography-tandem mass spectrometric assay for the cyclin-dependent kinase inhibitor AT7519 in mouse plasma. Journal of Pharmaceutical and Biomedical Analysis. 88: 216-20. PMID 24080524 DOI: 10.1016/j.jpba.2013.08.051  1
2014 Goey AK, Meijerman I, Rosing H, Marchetti S, Mergui-Roelvink M, Keessen M, Burgers JA, Beijnen JH, Schellens JH. The effect of St John's wort on the pharmacokinetics of docetaxel. Clinical Pharmacokinetics. 53: 103-10. PMID 24068654 DOI: 10.1007/s40262-013-0102-5  1
2014 Chuan Tang S, Nguyen LN, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH. Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. International Journal of Cancer. Journal International Du Cancer. 134: 1484-94. PMID 24037730 DOI: 10.1002/ijc.28475  1
2014 Hendrikx JJ, Rosing H, Schinkel AH, Schellens JH, Beijnen JH. Combined quantification of paclitaxel, docetaxel and ritonavir in human feces and urine using LC-MS/MS. Biomedical Chromatography : Bmc. 28: 302-10. PMID 23996474 DOI: 10.1002/bmc.3021  1
2014 Tang SC, Sparidans RW, Cheung KL, Fukami T, Durmus S, Wagenaar E, Yokoi T, Van Vlijmen BJM, Beijnen JH, Schinkel AH. P-glycoprotein, CYP3A, and plasma carboxylesterase determine brain and blood disposition of the mTOR inhibitor everolimus (Afinitor) in mice Clinical Cancer Research. 20: 3133-3145. DOI: 10.1158/1078-0432.CCR-13-1759  1
2014 Ter Heine R, Binkhorst L, De Graan AJM, De Bruijn P, Beijnen JH, Mathijssen RHJ, Huitema ADR. Population pharmacokinetic modelling to assess the impact of CYP2D6 and CYP3A metabolic phenotypes on the pharmacokinetics of tamoxifen and endoxifen British Journal of Clinical Pharmacology. 78: 572-586. DOI: 10.1111/bcp.12388  1
2014 Durmus S, Sparidans RW, van Esch A, Wagenaar E, Beijnen JH, Schinkel AH. Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) Restrict Oral Availability and Brain Accumulation of the PARP Inhibitor Rucaparib (AG-014699) Pharmaceutical Research. DOI: 10.1007/s11095-014-1442-z  1
2014 Huitema ADR, Schellens JHM, Beijnen JH. Monoclonal antibody conducts cytotoxic agent to tumor: New applications help in advance oncology | Monoklonaal antilichaam geleidt cytotoxische stof naar tumor: Nieuwe toepassingen helpen oncologie vooruit Pharmaceutische Weekblad Wetenschappelijk Platform. 149.  1
2014 Huitema ADR, Schellens JHM, Beijnen JH. New applications help advance oncology: Monoclonal antibody conducts cytotoxic agent to tumor | Nieuwe toepassingen helpen oncologie vooruit: Monoklonaal antilichaam geleidt cytotoxische stof naar tumor Pharmaceutisch Weekblad. 149: 26-29.  1
2014 Opdam FL, Huitema ADR, Beijnen JH, Schellens JHM. Hyperglycemia during treatment with everolimus | Hyperglykemie bij gebruik van everolimus Nederlands Tijdschrift Voor Geneeskunde. 158: S25-S34.  1
2014 Goey AKL, Meijerman I, Rosing H, Marchetti S, Mergui-Roelvink M, Keessen M, Burgers JA, Beijnen JH, Schellens JHM. The effect of St. John's wort on the pharmacokinetics of docetaxel | Farmacokinetische interactie tussen sint-janskruid en docetaxel Pharmaceutisch Weekblad. 149: 560-566.  1
2014 Hendrikx JJMA, Rosing H, Schinkel AH, Schellens JHM, Beijnen JH. Translational pharmacology of orally administered taxanes | Translationele farmacologie van oraal gegeven taxanen Pharmaceutisch Weekblad. 149: 26-29.  1
2013 Moes JJ, Stuurman FE, Hendrikx JJ, Marchetti S, Huitema AD, Beijnen JH, Schellens JH, Nuijen B. Pharmacokinetic evaluation of three oral formulations of docetaxel boosted with ritonavir: two single-drug formulations vs. a fixed-dose combination tablet. Drug Delivery and Translational Research. 3: 243-51. PMID 25788133 DOI: 10.1007/s13346-012-0127-6  1
2013 Lin F, de Gooijer MC, Hanekamp D, Brandsma D, Beijnen JH, van Tellingen O. Targeting core (mutated) pathways of high-grade gliomas: challenges of intrinsic resistance and drug efflux. Cns Oncology. 2: 271-88. PMID 25054467 DOI: 10.2217/cns.13.15  1
2013 Jager NG, Koornstra RH, Vincent AD, van Schaik RH, Huitema AD, Korse TM, Schellens JH, Linn SC, Beijnen JH. Hot flashes are not predictive for serum concentrations of tamoxifen and its metabolites. Bmc Cancer. 13: 612. PMID 24373320 DOI: 10.1186/1471-2407-13-612  1
2013 Slingerland M, Guchelaar HJ, Rosing H, Scheulen ME, van Warmerdam LJC, Beijnen JH, Gelderblom H. Bioequivalence of Liposome-Entrapped Paclitaxel Easy-To-Use (LEP-ETU) Formulation and Paclitaxel in Polyethoxylated Castor Oil: A Randomized, Two-Period Crossover Study in Patients With Advanced Cancer Clinical Therapeutics. 35: 1946-1954. PMID 24290734 DOI: 10.1016/j.clinthera.2013.10.009  1
2013 de Groot MH, van Campen JP, Moek MA, Tulner LR, Beijnen JH, Lamoth CJ. Authors' reply to Toda: "the effects of fall-risk-increasing drugs on postural control: a literature review". Drugs & Aging. 30: 1041-2. PMID 24197609 DOI: 10.1007/s40266-013-0132-6  1
2013 Nijenhuis CM, Lucas L, Rosing H, Schellens JH, Beijnen JH. Development and validation of a high-performance liquid chromatography-tandem mass spectrometry assay quantifying olaparib in human plasma. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 940: 121-5. PMID 24145016 DOI: 10.1016/j.jchromb.2013.09.020  1
2013 Van Eijk J, Van Campen JPCM, Van Der Jagt H, Beijnen JH, Tulner LR. Prevalence of xerostomia and its relationship with underlying diseases, medication, and nutrition: A descriptive observational study Journal of the American Geriatrics Society. 61: 1836-1837. PMID 24117307 DOI: 10.1111/jgs.12469  1
2013 Janssens T, Brouwers EE, de Vos JP, de Vries N, Schellens JH, Beijnen JH. Determination of platinum surface contamination in veterinary and human oncology centres using inductively coupled plasma mass spectrometry. Veterinary and Comparative Oncology. PMID 24034226 DOI: 10.1111/vco.12049  1
2013 Tang SC, Hendrikx JJ, Beijnen JH, Schinkel AH. Genetically modified mouse models for oral drug absorption and disposition. Current Opinion in Pharmacology. 13: 853-8. PMID 24021267 DOI: 10.1016/j.coph.2013.08.011  1
2013 de Groot MH, van Campen JP, Moek MA, Tulner LR, Beijnen JH, Lamoth CJ. The effects of fall-risk-increasing drugs on postural control: a literature review. Drugs & Aging. 30: 901-20. PMID 24005984 DOI: 10.1007/s40266-013-0113-9  1
2013 Lankheet NA, Huitema AD, Mallo H, Adriaansz S, Haanen JB, Schellens JH, Beijnen JH, Blank CU. The effect of seasonal variation and secretion of sunitinib in sweat on the development of hand-foot syndrome. European Journal of Clinical Pharmacology. 69: 2065-72. PMID 23995862 DOI: 10.1007/s00228-013-1579-4  1
2013 Jacobs PL, Ridder L, Ruijken M, Rosing H, Jager NG, Beijnen JH, Bas RR, van Dongen WD. Identification of drug metabolites in human plasma or serum integrating metabolite prediction, LC-HRMS and untargeted data processing. Bioanalysis. 5: 2115-28. PMID 23962251 DOI: 10.4155/bio.13.178  1
2013 Hendrikx JJ, Dubbelman AC, Rosing H, Schinkel AH, Schellens JH, Beijnen JH. Quantification of docetaxel and its metabolites in human plasma by liquid chromatography/tandem mass spectrometry. Rapid Communications in Mass Spectrometry : Rcm. 27: 1925-34. PMID 23939959 DOI: 10.1002/rcm.6654  1
2013 Luethi D, Durmus S, Schinkel AH, Schellens JH, Beijnen JH, Sparidans RW. Liquid chromatography-tandem mass spectrometry assay for the EGFR inhibitor pelitinib in plasma. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 934: 22-5. PMID 23892825 DOI: 10.1016/j.jchromb.2013.06.030  1
2013 Goey AK, Meijerman I, Beijnen JH, Schellens JH. The effect of grape seed extract on the pharmacokinetics of dextromethorphan in healthy volunteers. European Journal of Clinical Pharmacology. 69: 1883-90. PMID 23881421 DOI: 10.1007/s00228-013-1558-9  1
2013 Lau C, Mooiman KD, Maas-Bakker RF, Beijnen JH, Schellens JH, Meijerman I. Effect of Chinese herbs on CYP3A4 activity and expression in vitro. Journal of Ethnopharmacology. 149: 543-9. PMID 23876595 DOI: 10.1016/j.jep.2013.07.014  1
2013 Tang SC, de Vries N, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH. Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) gene dosage on plasma pharmacokinetics and brain accumulation of dasatinib, sorafenib, and sunitinib. The Journal of Pharmacology and Experimental Therapeutics. 346: 486-94. PMID 23843632 DOI: 10.1124/jpet.113.205583  1
2013 Durmus S, Xu N, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH. P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) restrict brain accumulation of the JAK1/2 inhibitor, CYT387. Pharmacological Research. 76: 9-16. PMID 23827160 DOI: 10.1016/j.phrs.2013.06.009  1
2013 van der Heijden I, Beijnen JH, Nuijen B. Long term stability of lyophilized plasmid DNA pDERMATT. International Journal of Pharmaceutics. 453: 648-50. PMID 23792100 DOI: 10.1016/j.ijpharm.2013.06.010  1
2013 Stuurman FE, Lolkema MP, Huitema AD, Soetekouw PM, Rosing H, Rolfe L, Kaur P, Beijnen JH, van Tinteren H, Voest EE, Schellens JH. A phase 1 comparative pharmacokinetic and cardiac safety study of two intravenous formulations of CO-101 in patients with advanced solid tumors. Journal of Clinical Pharmacology. 53: 878-83. PMID 23775853 DOI: 10.1002/jcph.108  1
2013 Dorlo TP, Ostyn BA, Beijnen JH, Boelaert M, Dujardin JC, Rijal S. Reply to Arya and Agarwal. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 57: 917-8. PMID 23759350 DOI: 10.1093/cid/cit388  1
2013 van der Heijden I, Gomez-Eerland R, van den Berg JH, Oosterhuis K, Schumacher TN, Haanen JB, Beijnen JH, Nuijen B. Transposon leads to contamination of clinical pDNA vaccine. Vaccine. 31: 3274-80. PMID 23707695 DOI: 10.1016/j.vaccine.2013.05.022  1
2013 Goey AK, Meijerman I, Rosing H, Burgers JA, Mergui-Roelvink M, Keessen M, Marchetti S, Beijnen JH, Schellens JH. The effect of Echinacea purpurea on the pharmacokinetics of docetaxel. British Journal of Clinical Pharmacology. 76: 467-74. PMID 23701184 DOI: 10.1111/bcp.12159  1
2013 Mooiman KD, Maas-Bakker RF, Moret EE, Beijnen JH, Schellens JH, Meijerman I. Milk thistle's active components silybin and isosilybin: novel inhibitors of PXR-mediated CYP3A4 induction. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 41: 1494-504. PMID 23674609 DOI: 10.1124/dmd.113.050971  1
2013 Mooiman KD, Maas-Bakker RF, Rosing H, Beijnen JH, Schellens JH, Meijerman I. Development and validation of a LC-MS/MS method for the in vitro analysis of 1-hydroxymidazolam in human liver microsomes: application for determining CYP3A4 inhibition in complex matrix mixtures. Biomedical Chromatography : Bmc. 27: 1107-16. PMID 23674377 DOI: 10.1002/bmc.2913  1
2013 Derissen EJ, Beijnen JH, Schellens JH. Concise drug review: azacitidine and decitabine. The Oncologist. 18: 619-24. PMID 23671007 DOI: 10.1634/theoncologist.2012-0465  1
2013 Leijen S, Veltkamp SA, Huitema AD, van Werkhoven E, Beijnen JH, Schellens JH. Phase I dose-escalation study and population pharmacokinetic analysis of fixed dose rate gemcitabine plus carboplatin as second-line therapy in patients with ovarian cancer. Gynecologic Oncology. 130: 511-7. PMID 23665458 DOI: 10.1016/j.ygyno.2013.05.001  1
2013 Jibodh RA, Lagas JS, Nuijen B, Beijnen JH, Schellens JH. Taxanes: old drugs, new oral formulations. European Journal of Pharmacology. 717: 40-6. PMID 23660368 DOI: 10.1016/j.ejphar.2013.02.058  1
2013 Dorlo TP, Jager NG, Beijnen JH, Schellens JH. [Concomitant use of proton pump inhibitors and systemic corticosteroids]. Nederlands Tijdschrift Voor Geneeskunde. 157: A5540. PMID 23657097  1
2013 van Hasselt JG, Gupta A, Hussein Z, Beijnen JH, Schellens JH, Huitema AD. Population pharmacokinetic-pharmacodynamic analysis for eribulin mesilate-associated neutropenia. British Journal of Clinical Pharmacology. 76: 412-24. PMID 23601153 DOI: 10.1111/bcp.12143  1
2013 Kort A, Hillebrand MJ, Cirkel GA, Voest EE, Schinkel AH, Rosing H, Schellens JH, Beijnen JH. Quantification of cabazitaxel, its metabolite docetaxel and the determination of the demethylated metabolites RPR112698 and RPR123142 as docetaxel equivalents in human plasma by liquid chromatography-tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 925: 117-23. PMID 23542607 DOI: 10.1016/j.jchromb.2013.02.034  1
2013 Sparidans RW, Durmus S, Schinkel AH, Schellens JH, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for the mutated BRAF inhibitor dabrafenib in mouse plasma. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 925: 124-8. PMID 23537694 DOI: 10.1016/j.jchromb.2013.02.025  1
2013 van den Hoven JM, Nemes R, Metselaar JM, Nuijen B, Beijnen JH, Storm G, Szebeni J. Complement activation by PEGylated liposomes containing prednisolone. European Journal of Pharmaceutical Sciences : Official Journal of the European Federation For Pharmaceutical Sciences. 49: 265-71. PMID 23528740 DOI: 10.1016/j.ejps.2013.03.007  1
2013 Radhakishun NN, van Vliet M, von Rosenstiel IA, Weijer O, Beijnen JH, Brandjes DP, Diamant M. Increasing thyroid-stimulating hormone is associated with impaired glucose metabolism in euthyroid obese children and adolescents. Journal of Pediatric Endocrinology & Metabolism : Jpem. 26: 531-7. PMID 23525871 DOI: 10.1515/jpem-2012-0302  1
2013 Deenen MJ, Dewit L, Boot H, Beijnen JH, Schellens JH, Cats A. Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study. International Journal of Radiation Oncology, Biology, Physics. 85: e201-7. PMID 23517808 DOI: 10.1016/j.ijrobp.2012.12.008  1
2013 Radhakishun NN, van Vliet M, von Rosenstiel IA, Beijnen JH, Diamant M. Limited value of routine microalbuminuria assessment in multi-ethnic obese children. Pediatric Nephrology (Berlin, Germany). 28: 1145-9. PMID 23503768 DOI: 10.1007/s00467-013-2451-6  1
2013 Lankheet NA, Steeghs N, Rosing H, Schellens JH, Beijnen JH, Huitema AD. Quantification of sunitinib and N-desethyl sunitinib in human EDTA plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry: validation and application in routine therapeutic drug monitoring. Therapeutic Drug Monitoring. 35: 168-76. PMID 23503442 DOI: 10.1097/FTD.0b013e31827efd9e  1
2013 Lin F, Marchetti S, Pluim D, Iusuf D, Mazzanti R, Schellens JH, Beijnen JH, van Tellingen O. Abcc4 together with abcb1 and abcg2 form a robust cooperative drug efflux system that restricts the brain entry of camptothecin analogues. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 2084-95. PMID 23461902 DOI: 10.1158/1078-0432.CCR-12-3105  1
2013 Kromdijk W, Sikma MA, van den Broek MP, Beijnen JH, Huitema AD, de Lange DW. Pharmacokinetics of oseltamivir carboxylate in critically ill patients: each patient is unique. Intensive Care Medicine. 39: 977-8. PMID 23443310 DOI: 10.1007/s00134-013-2851-x  1
2013 Lin F, Buil L, Sherris D, Beijnen JH, van Tellingen O. Dual mTORC1 and mTORC2 inhibitor Palomid 529 penetrates the blood-brain barrier without restriction by ABCB1 and ABCG2. International Journal of Cancer. Journal International Du Cancer. 133: 1222-33. PMID 23436212 DOI: 10.1002/ijc.28126  1
2013 van der Noll R, Leijen S, Neuteboom GH, Beijnen JH, Schellens JH. Effect of inhibition of the FGFR-MAPK signaling pathway on the development of ocular toxicities. Cancer Treatment Reviews. 39: 664-72. PMID 23434072 DOI: 10.1016/j.ctrv.2013.01.003  1
2013 Rijal S, Ostyn B, Uranw S, Rai K, Bhattarai NR, Dorlo TP, Beijnen JH, Vanaerschot M, Decuypere S, Dhakal SS, Das ML, Karki P, Singh R, Boelaert M, Dujardin JC. Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 56: 1530-8. PMID 23425958 DOI: 10.1093/cid/cit102  1
2013 Lin F, Hoogendijk L, Buil L, Beijnen JH, van Tellingen O. Sildenafil is not a useful modulator of ABCB1 and ABCG2 mediated drug resistance in vivo. European Journal of Cancer (Oxford, England : 1990). 49: 2059-64. PMID 23422148 DOI: 10.1016/j.ejca.2012.12.028  1
2013 Stuurman FE, Nuijen B, Beijnen JH, Schellens JH. Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement. Clinical Pharmacokinetics. 52: 399-414. PMID 23420518 DOI: 10.1007/s40262-013-0040-2  1
2013 Kromdijk W, Pereira SA, Rosing H, Mulder JW, Beijnen JH, Huitema AD. Development and validation of an assay for the simultaneous determination of zidovudine, abacavir, emtricitabine, lamivudine, tenofovir and ribavirin in human plasma using liquid chromatography-tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 919: 43-51. PMID 23411018 DOI: 10.1016/j.jchromb.2013.01.005  1
2013 Goey AK, Mooiman KD, Beijnen JH, Schellens JH, Meijerman I. Relevance of in vitro and clinical data for predicting CYP3A4-mediated herb-drug interactions in cancer patients. Cancer Treatment Reviews. 39: 773-83. PMID 23394826 DOI: 10.1016/j.ctrv.2012.12.008  1
2013 Balkenende EM, Dahhan T, Linn SC, Jager NG, Beijnen JH, Goddijn M. A prospective case series of women with estrogen receptor-positive breast cancer: levels of tamoxifen metabolites in controlled ovarian stimulation with high-dose tamoxifen. Human Reproduction (Oxford, England). 28: 953-9. PMID 23335608 DOI: 10.1093/humrep/des445  1
2013 Deenen MJ, Cats A, Beijnen JH, Schellens JH. Standard-dose tegafur-uracil (UFT) is not a safe alternative in partial dihydropyrimidine dehydrogenase-deficient patients. Therapeutic Advances in Medical Oncology. 5: 91-2. PMID 23323150 DOI: 10.1177/1758834012464806  1
2013 Dubbelman AC, Rosing H, Darwish M, D'Andrea D, Bond M, Hellriegel E, Robertson P, Beijnen JH, Schellens JH. Pharmacokinetics and excretion of 14C-bendamustine in patients with relapsed or refractory malignancy. Drugs in R&D. 13: 17-28. PMID 23322528 DOI: 10.1007/s40268-012-0001-5  1
2013 Pluim D, Jacobs BA, Krähenbühl MD, Ruijter AE, Beijnen JH, Schellens JH. Correction of peripheral blood mononuclear cell cytosolic protein for hemoglobin contamination. Analytical and Bioanalytical Chemistry. 405: 2391-5. PMID 23318760 DOI: 10.1007/s00216-012-6614-2  1
2013 Marchetti S, Pluim D, Van Eijndhoven M, Van Tellingen O, Mazzanti R, Beijnen JH, Schellens JHM. Effect of the drug transporters ABCG2, Abcg2, ABCB1 and ABCC2 on the disposition, brain accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib-hydroxy-QPA Investigational New Drugs. 31: 1125-1135. PMID 23315030 DOI: 10.1007/s10637-013-9923-1  1
2013 Pluim D, Schilders KA, Jacobs BA, Vaartjes D, Beijnen JH, Schellens JH. Pharmacodynamic assay of thymidylate synthase activity in peripheral blood mononuclear cells. Analytical and Bioanalytical Chemistry. 405: 2495-503. PMID 23314484 DOI: 10.1007/s00216-012-6676-1  1
2013 Zander SA, Beijnen JH, van Tellingen O. Sensitive method for plasma and tumor Ko143 quantification using reversed-phase high-performance liquid chromatography and fluorescence detection. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 913: 129-36. PMID 23291288 DOI: 10.1016/j.jchromb.2012.11.003  1
2013 Harmsen S, Meijerman I, Maas-Bakker RF, Beijnen JH, Schellens JHM. PXR-mediated P-glycoprotein induction by small molecule tyrosine kinase inhibitors European Journal of Pharmaceutical Sciences. 48: 644-649. PMID 23277288 DOI: 10.1016/j.ejps.2012.12.019  1
2013 Deenen MJ, Rosing H, Hillebrand MJ, Schellens JH, Beijnen JH. Quantitative determination of capecitabine and its six metabolites in human plasma using liquid chromatography coupled to electrospray tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 913: 30-40. PMID 23270936 DOI: 10.1016/j.jchromb.2012.11.033  1
2013 Kromdijk W, Mulder JW, Smit PM, Ter Heine R, Beijnen JH, Huitema AD. Therapeutic drug monitoring of antiretroviral drugs at home using dried blood spots: a proof-of-concept study. Antiviral Therapy. 18: 821-5. PMID 23234680 DOI: 10.3851/IMP2501  1
2013 Meulenaar J, Beijnen JH, Schellens JH, Nuijen B. Slow dissolution behaviour of amorphous capecitabine. International Journal of Pharmaceutics. 441: 213-7. PMID 23219704 DOI: 10.1016/j.ijpharm.2012.11.041  1
2013 Van Hasselt JGC, van Eijkelenburg NKA, Beijnen JH, Schellens JHM, Huitema ADR. Optimizing drug development of anti-cancer drugs in children using modelling and simulation British Journal of Clinical Pharmacology. 76: 30-47. PMID 23216601 DOI: 10.1111/bcp.12062  1
2013 Nijenhuis CM, Haanen JBAG, Schellens JHM, Beijnen JH. Is combination therapy the next step to overcome resistance and reduce toxicities in melanoma? Cancer Treatment Reviews. 39: 305-312. PMID 23207060 DOI: 10.1016/j.ctrv.2012.10.006  1
2013 Smit PM, Pronk SM, Kaandorp JC, Weijer O, Lauw FN, Smits PH, Claas EC, Mulder JW, Beijnen JH, Brandjes DP. RT-PCR detection of respiratory pathogens in newborn children admitted to a neonatal medium care unit. Pediatric Research. 73: 355-61. PMID 23202720 DOI: 10.1038/pr.2012.176  1
2013 Hendrikx JJ, Lagas JS, Rosing H, Schellens JH, Beijnen JH, Schinkel AH. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel. International Journal of Cancer. Journal International Du Cancer. 132: 2439-47. PMID 23090875 DOI: 10.1002/ijc.27912  1
2013 Milojkovic Kerklaan B, Kerklaan BM, Diéras V, Le Tourneau C, Mergui-Roelvink M, Huitema AD, Rosing H, Beijnen JH, Marreaud S, Govaerts AS, Piccart-Gebhart MJ, Schellens JH, Awada A. Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023. Cancer Chemotherapy and Pharmacology. 71: 53-62. PMID 23053259 DOI: 10.1007/s00280-012-1972-1  1
2013 Lankheet NA, Hillebrand MJ, Rosing H, Schellens JH, Beijnen JH, Huitema AD. Method development and validation for the quantification of dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, sorafenib and sunitinib in human plasma by liquid chromatography coupled with tandem mass spectrometry. Biomedical Chromatography : Bmc. 27: 466-76. PMID 22987603 DOI: 10.1002/bmc.2814  1
2013 Devriese LA, Witteveen PE, Wanders J, Law K, Edwards G, Reyderman L, Copalu W, Peng F, Marchetti S, Beijnen JH, Huitema AD, Voest EE, Schellens JH. Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin. British Journal of Clinical Pharmacology. 75: 507-15. PMID 22803519 DOI: 10.1111/j.1365-2125.2012.04381.x  1
2013 Devriese LA, Mergui-Roelvink M, Wanders J, Jenner A, Edwards G, Reyderman L, Copalu W, Peng F, Marchetti S, Beijnen JH, Schellens JHM. Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole Investigational New Drugs. 31: 381-389. PMID 22555773 DOI: 10.1007/s10637-012-9829-3  1
2013 De Jager A, Schellens JHM, Beijnen JH, Huitema ADR. Trastuzumab emtansine (T-DM1): An antibody-drug conjugate for targeted treatment of HER2-positive metastatic breast cancer | Trastuzumab emtansine (T-DM1): Een antilichaamgeneesmiddelconjugaat voor gerichte behandeling van HER2-positieve gemetastaseerde borstkanker Pharmaceutisch Weekblad. 148: 132-135.  1
2013 Van Keep MML, Huitema ADR, Schellens JHM, Beijnen JH. Eribulin: New oncolytic agent for the treatment of metastatic breast cancer | Eribuline: Nieuw oncolyticum voor de behandeling van gemetastaseerde borstkanker Pharmaceutisch Weekblad. 148: 60-64.  1
2013 Deenen MJ, Cats A, Mandigers CMPW, Soesan M, Terpstra WE, Beijnen JH, Schellens JHM. Prevention of severe toxicity in chemotherapy: Screening for dihydropyrimidinedehydrogenase deficiency in capecitabine, 5-fluorouracil and tegafur | Voorkómen van ernstige toxiciteit bij chemotherapie Nederlands Tijdschrift Voor Geneeskunde. 157.  1
2012 Deenen MJ, Cats A, Mandigers CM, Soesan M, Terpstra WE, Beijnen JH, Schellens JH. [Prevention of severe toxicity from capecitabine, 5-fluorouracil and tegafur by screening for DPD-deficiency]. Nederlands Tijdschrift Voor Geneeskunde. 156: A4934. PMID 23191966  1
2012 Lankheet NA, Schaake EE, Rosing H, Burgers JA, Schellens JH, Beijnen JH, Huitema AD. Quantitative determination of erlotinib and O-desmethyl erlotinib in human EDTA plasma and lung tumor tissue. Bioanalysis. 4: 2563-77. PMID 23173792 DOI: 10.4155/bio.12.235  1
2012 Dorlo TP, Ravinetto RM, Beijnen JH, Boelaert M. Commentary: Substandard medicines are the priority for neglected tropical diseases. Bmj (Clinical Research Ed.). 345: e7518. PMID 23152570 DOI: 10.1136/bmj.e7518  1
2012 Dorlo TP, Boelaert M, Beijnen JH, Ravinetto R. Universal access to quality medicines: prioritisation of a-priori solutions. The Lancet. Infectious Diseases. 12: 829-30. PMID 23099080 DOI: 10.1016/S1473-3099(12)70259-1  1
2012 Durmus S, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH. Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. Molecular Pharmaceutics. 9: 3236-45. PMID 23020847 DOI: 10.1021/mp3003144  1
2012 Devriese LA, Witteveen PO, Marchetti S, Mergui-Roelvink M, Reyderman L, Wanders J, Jenner A, Edwards G, Beijnen JH, Voest EE, Schellens JHM. Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment Cancer Chemotherapy and Pharmacology. 70: 823-832. PMID 23010853 DOI: 10.1007/s00280-012-1976-x  1
2012 Dubbelman AC, Upthagrove A, Beijnen JH, Marchetti S, Tan E, Krone K, Anand S, Schellens JH. Disposition and metabolism of 14C-dovitinib (TKI258), an inhibitor of FGFR and VEGFR, after oral administration in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 70: 653-63. PMID 23010851 DOI: 10.1007/s00280-012-1947-2  1
2012 Swartjes M, Mooren RA, Waxman AR, Arout C, van de Wetering K, den Hartigh J, Beijnen JH, Kest B, Dahan A. Morphine induces hyperalgesia without involvement of μ-opioid receptor or morphine-3-glucuronide. Molecular Medicine (Cambridge, Mass.). 18: 1320-6. PMID 23001479 DOI: 10.2119/molmed.2012.00244  1
2012 Van Den Hoven JM, Metselaar JM, Storm G, Beijnen JH, Nuijen B. Cyclodextrin as membrane protectant in spray-drying and freeze-drying of PEGylated liposomes International Journal of Pharmaceutics. 438: 209-216. PMID 22960501 DOI: 10.1016/j.ijpharm.2012.08.046  1
2012 Sparidans RW, Tang SC, Nguyen LN, Schinkel AH, Schellens JH, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for the ALK inhibitor crizotinib in mouse plasma. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 905: 150-4. PMID 22940474 DOI: 10.1016/j.jchromb.2012.08.021  1
2012 Sparidans RW, Ahmed TTA, Muilwijk EW, Welzen MEB, Schellens JHM, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the tyrosine kinase inhibitor pazopanib in human plasma Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences. 905: 137-140. PMID 22917595 DOI: 10.1016/j.jchromb.2012.08.004  1
2012 Van Hasselt JGC, Schellens JHM, Mac Gillavry MR, Beijnen JH, Huitema ADR. Model-based evaluation and optimization of cardiac monitoring protocols for adjuvant treatment of breast cancer with trastuzumab Pharmaceutical Research. 29: 3499-3511. PMID 22907417 DOI: 10.1007/s11095-012-0845-y  1
2012 Dorlo TPC, Balasegaram M, Beijnen JH, de vries PJ. Miltefosine: A review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis Journal of Antimicrobial Chemotherapy. 67: 2576-2597. PMID 22833634 DOI: 10.1093/jac/dks275  1
2012 Joerger M, Kraff S, Huitema AD, Feiss G, Moritz B, Schellens JH, Beijnen JH, Jaehde U. Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study. Clinical Pharmacokinetics. 51: 607-17. PMID 22804749 DOI: 10.1007/BF03261934  1
2012 Lagas JS, Damen CWN, Van Waterschoot RAB, Iusuf D, Beijnen JH, Schinkel AH. P-glycoprotein, multidrug-resistance associated protein 2, Cyp3a, and carboxylesterase affect the oral availability and metabolism of vinorelbine Molecular Pharmacology. 82: 636-644. PMID 22767610 DOI: 10.1124/mol.111.077099  1
2012 Lin F, Chandrasekaran G, de Gooijer MC, Beijnen JH, van Tellingen O. Determination of NVP-BEZ235, a dual PI3K and mTOR inhibitor, in human and mouse plasma and in mouse tissue homogenates by reversed-phase high-performance liquid chromatography with fluorescence detection. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 901: 9-17. PMID 22727754 DOI: 10.1016/j.jchromb.2012.05.033  0.52
2012 Keizer RJ, Zandvliet AS, Beijnen JH, Schellens JH, Huitema AD. Performance of methods for handling missing categorical covariate data in population pharmacokinetic analyses. The Aaps Journal. 14: 601-11. PMID 22648902 DOI: 10.1208/s12248-012-9373-2  0.84
2012 Dorlo TP, Huitema AD, Beijnen JH, de Vries PJ. Optimal dosing of miltefosine in children and adults with visceral leishmaniasis. Antimicrobial Agents and Chemotherapy. 56: 3864-72. PMID 22585212 DOI: 10.1128/AAC.00292-12  0.72
2012 Dorlo TP, Balasegaram M, Lima MA, de Vries PJ, Beijnen JH, Huitema AD. Translational pharmacokinetic modelling and simulation for the assessment of duration of contraceptive use after treatment with miltefosine. The Journal of Antimicrobial Chemotherapy. 67: 1996-2004. PMID 22577099 DOI: 10.1093/jac/dks164  0.72
2012 Boss DS, Glen H, Beijnen JH, Keesen M, Morrison R, Tait B, Copalu W, Mazur A, Wanders J, O'Brien JP, Schellens JH, Evans TR. A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours. British Journal of Cancer. 106: 1598-604. PMID 22516948 DOI: 10.1038/bjc.2012.154  0.84
2012 Dubbelman AC, Jansen RS, Rosing H, Darwish M, Hellriegel E, Robertson P, Schellens JH, Beijnen JH. Metabolite profiling of bendamustine in urine of cancer patients after administration of [14C]bendamustine. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 40: 1297-307. PMID 22492615 DOI: 10.1124/dmd.112.045229  1
2012 Dubbelman AC, Tibben M, Rosing H, Gebretensae A, Nan L, Gorman SH, Robertson P, Schellens JH, Beijnen JH. Development and validation of LC-MS/MS assays for the quantification of bendamustine and its metabolites in human plasma and urine. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 893: 92-100. PMID 22426286 DOI: 10.1016/j.jchromb.2012.02.039  1
2012 Kromdijk W, Rosing H, van den Broek MP, Beijnen JH, Huitema AD. Quantitative determination of oseltamivir and oseltamivir carboxylate in human fluoride EDTA plasma including the ex vivo stability using high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 891: 57-63. PMID 22418071 DOI: 10.1016/j.jchromb.2012.02.026  1
2012 Jager NG, Rosing H, Linn SC, Schellens JH, Beijnen JH. Importance of highly selective LC-MS/MS analysis for the accurate quantification of tamoxifen and its metabolites: focus on endoxifen and 4-hydroxytamoxifen. Breast Cancer Research and Treatment. 133: 793-8. PMID 22388692 DOI: 10.1007/s10549-012-2000-1  1
2012 Jansen RS, Rosing H, Wijermans PW, Keizer RJ, Schellens JH, Beijnen JH. Decitabine triphosphate levels in peripheral blood mononuclear cells from patients receiving prolonged low-dose decitabine administration: a pilot study. Cancer Chemotherapy and Pharmacology. 69: 1457-66. PMID 22382880 DOI: 10.1007/s00280-012-1850-x  1
2012 Dubbelman AC, Rosing H, Thijssen B, Gebretensae A, Lucas L, Chen H, Shumaker R, Schellens JHM, Beijnen JH. Development and validation of LC-MS/MS assays for the quantification of E7080 and metabolites in various human biological matrices Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences. 887: 25-34. PMID 22309776 DOI: 10.1016/j.jchromb.2012.01.004  1
2012 Kromdijk W, Mulder JW, Rosing H, Smit PM, Beijnen JH, Huitema AD. Use of dried blood spots for the determination of plasma concentrations of nevirapine and efavirenz. The Journal of Antimicrobial Chemotherapy. 67: 1211-6. PMID 22302563 DOI: 10.1093/jac/dks011  1
2012 Keizer RJ, Gupta A, Shumaker R, Beijnen JH, Schellens JH, Huitema AD. Model-based treatment optimization of a novel VEGFR inhibitor. British Journal of Clinical Pharmacology. 74: 315-26. PMID 22295876 DOI: 10.1111/j.1365-2125.2012.04197.x  1
2012 Vermaat JS, Gerritse FL, Van Der Veldt AA, Roessingh WM, Niers TM, Oosting SF, Sleijfer S, Roodhart JM, Beijnen JH, Schellens JH, Gietema JA, Boven E, Richel DJ, Haanen JB, Voest EE. Validation of serum amyloid α as an independent biomarker for progression-free and overall survival in metastatic renal cell cancer patients European Urology. 62: 685-696. PMID 22285764 DOI: 10.1016/j.eururo.2012.01.020  1
2012 Manson ML, Derissen EJB, Wijermans PW, Schellens JHM, Beijnen JH. [Demethylating medication in myelodysplastic syndrome]. | Demethylerende medicatie bij myelodysplastisch syndroom: epigenetica als target voor therapie Nederlands Tijdschrift Voor Geneeskunde. 156: A3167. PMID 22278034  1
2012 Tran L, Huitema AD, Vogel WV, Beijnen JH, Baars JW. Lack of tumor uptake of 131-I labeled rituximab in a patient with a CD20 positive lymphoma lesion. Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners. 18: 417-20. PMID 22228555 DOI: 10.1177/1078155211428998  1
2012 ter Heine R, van den Bosch RT, Schaefer-Prokop CM, Lankheet NA, Beijnen JH, Staaks GH, van der Westerlaken MM, Malingré MM, van den Brand JJ. Fatal interstitial lung disease associated with high erlotinib and metabolite levels. A case report and a review of the literature. Lung Cancer (Amsterdam, Netherlands). 75: 391-7. PMID 22101147 DOI: 10.1016/j.lungcan.2011.10.008  0.32
2012 Dubbelman AC, Rosing H, Jansen RS, Mergui-Roelvink M, Huitema AD, Koetz B, Lymboura M, Reyderman L, Lopez-Anaya A, Schellens JH, Beijnen JH. Mass balance study of [¹⁴C]eribulin in patients with advanced solid tumors. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 40: 313-21. PMID 22041109 DOI: 10.1124/dmd.111.042762  1
2012 Joerger M, Burgers SA, Baas P, Smit EF, Haitjema TJ, Bard MP, Doodeman VD, Smits PH, Vincent A, Huitema AD, Beijnen JH, Schellens JH. Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study. Cancer. 118: 2466-75. PMID 22031394 DOI: 10.1002/cncr.26562  1
2012 Keizer RJ, Zandvliet AS, Beijnen JH, Schellens JH, Huitema AD. Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152). Investigational New Drugs. 30: 1519-30. PMID 21626115 DOI: 10.1007/s10637-011-9694-5  0.84
2012 Joerger M, Burgers JA, Baas P, Doodeman VD, Smits PH, Jansen RS, Vainchtein LD, Rosing H, Huitema AD, Beijnen JH, Schellens JH. Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine. Cancer Chemotherapy and Pharmacology. 69: 25-33. PMID 21590444 DOI: 10.1007/s00280-011-1670-4  1
2012 Keizer RJ, Budde IK, Sprengers PF, Levi M, Beijnen JH, Huitema AD. Model-based evaluation of similarity in pharmacokinetics of two formulations of the blood-derived plasma product c1 esterase inhibitor. Journal of Clinical Pharmacology. 52: 204-13. PMID 21263014 DOI: 10.1177/0091270010394446  0.72
2012 Huitema ADR, Schellens JHM, Beijnen JH. Adjustment needed for dosing guidelines on antineoplastic agents: Expert panel maintains body surface area | Aanpassing nodig van doseerrichtlijnen oncolytica: Expertpanel handhaaftlichaamsoppervlak Pharmaceutisch Weekblad. 147: 28-31.  1
2012 Nijenhuis CM, Schellens JHM, Beijnen JH. Vemurafenib: New developments in the treatment of metastatic melanoma | Vemurafenib: Nieuwe ontwikkelingen bij de behandeling van gemetastaseerd melanoom Pharmaceutisch Weekblad. 147: 182-188.  1
2011 Joerger M, Burgers SA, Baas P, Smit EF, Haitjema TJ, Bard MP, Doodeman VD, Smits PH, Vincent A, Huitema A, Beijnen JH, Schellens JH. Drug pathway-associated gene polymorphisms in patients with advanced non-small cell lung cancer receiving first-line platinum-gemcitabine combination chemotherapy: A prospective multicenter observational study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 7536. PMID 28023228 DOI: 10.1200/jco.2011.29.15_suppl.7536  0.84
2011 Devriese LA, Witteveen P, Voest EE, Overkleeft EN, Langenberg M, Beijnen JH, Reyderman L, Wanders J, Mould DR, Gupta A, Hussein Z, Schellens JH. Eribulin dosing in patients with advanced solid tumors and hepatic impairment. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2544. PMID 28022319 DOI: 10.1200/jco.2011.29.15_suppl.2544  0.84
2011 Lankheet NA, Blank CU, Mallo H, Adriaansz S, Rosing H, Schellens JH, Huitema AD, Beijnen JH. Determination of sunitinib and its active metabolite N-desethylsunitinib in sweat of a patient. Journal of Analytical Toxicology. 35: 558-65. PMID 22004675 DOI: 10.1093/ANATOX/35.8.558  1
2011 Roodhart JM, Daenen LG, Stigter EC, Prins HJ, Gerrits J, Houthuijzen JM, Gerritsen MG, Schipper HS, Backer MJ, van Amersfoort M, Vermaat JS, Moerer P, Ishihara K, Kalkhoven E, Beijnen JH, et al. Mesenchymal stem cells induce resistance to chemotherapy through the release of platinum-induced fatty acids. Cancer Cell. 20: 370-83. PMID 21907927 DOI: 10.1016/j.ccr.2011.08.010  1
2011 Moes JJ, Koolen SL, Huitema AD, Schellens JH, Beijnen JH, Nuijen B. Pharmaceutical development and preliminary clinical testing of an oral solid dispersion formulation of docetaxel (ModraDoc001). International Journal of Pharmaceutics. 420: 244-50. PMID 21907780 DOI: 10.1016/j.ijpharm.2011.08.041  0.84
2011 Opstal-van Winden AW, Krop EJ, Kåredal MH, Gast MC, Lindh CH, Jeppsson MC, Jönsson BA, Grobbee DE, Peeters PH, Beijnen JH, van Gils CH, Vermeulen RC. Searching for early breast cancer biomarkers by serum protein profiling of pre-diagnostic serum; a nested case-control study. Bmc Cancer. 11: 381. PMID 21871081 DOI: 10.1186/1471-2407-11-381  1
2011 Caron WP, Clewell H, Dedrick R, Ramanathan RK, Davis WL, Yu N, Tonda M, Schellens JH, Beijnen JH, Zamboni WC. Allometric scaling of pegylated liposomal anticancer drugs. Journal of Pharmacokinetics and Pharmacodynamics. 38: 653-69. PMID 21863380 DOI: 10.1007/s10928-011-9213-5  1
2011 de Graan AJ, Teunissen SF, de Vos FY, Loos WJ, van Schaik RH, de Jongh FE, de Vos AI, van Alphen RJ, van der Holt B, Verweij J, Seynaeve C, Beijnen JH, Mathijssen RH. Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3240-6. PMID 21768449 DOI: 10.1200/JCO.2010.32.9839  1
2011 Koolen SL, Witteveen PO, Jansen RS, Langenberg MH, Kronemeijer RH, Nol A, Garcia-Ribas I, Callies S, Benhadji KA, Slapak CA, Beijnen JH, Voest EE, Schellens JH. Phase I study of Oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 6071-82. PMID 21753156 DOI: 10.1158/1078-0432.CCR-11-0353  0.84
2011 Smit PM, Veldhuis S, Mulder JW, Roggeveen C, Rimmelzwaan GF, Meijers JC, Beijnen JH, Brandjes DP. Influenza vaccination and hemostasis: no sustainable procoagulant effects from 2009 H1N1 influenza vaccine in healthy healthcare workers. Journal of Thrombosis and Haemostasis : Jth. 9: 1659-61. PMID 21696536 DOI: 10.1111/j.1538-7836.2011.04413.x  0.32
2011 Tran L, Baars JW, de Boer JP, Hoefnagel CA, Beijnen JH, Huitema AD. The pharmacokinetics of ¹³¹I-rituximab in a patient with CD20 positive non-Hodgkin Lymphoma: evaluation of the effect of radioiodination on the biological properties of rituximab. Human Antibodies. 20: 37-40. PMID 21558622 DOI: 10.3233/HAB20110240  0.72
2011 Tran L, Huitema AD, van Rijswijk MH, Dinant HJ, Baars JW, Beijnen JH, Vogel WV. CD20 antigen imaging with ¹²⁴I-rituximab PET/CT in patients with rheumatoid arthritis. Human Antibodies. 20: 29-35. PMID 21558621 DOI: 10.3233/HAB20110239  0.72
2011 Tran L, Vogel WV, Sinaasappel M, Muller S, Baars JW, van Rijswijk M, Dinant HJ, Beijnen JH, Huitema AD. The pharmacokinetics of ¹²⁴I-rituximab in patients with rheumatoid arthritis. Human Antibodies. 20: 7-14. PMID 21558619 DOI: 10.3233/HAB20110237  0.72
2011 Joerger M, deJong D, Burylo A, Burgers JA, Baas P, Huitema AD, Beijnen JH, Schellens JH. Tubulin, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy. Lung Cancer (Amsterdam, Netherlands). 74: 310-7. PMID 21529986 DOI: 10.1016/j.lungcan.2011.03.016  1
2011 ter Heine R, Van Waterschoot RA, Keizer RJ, Beijnen JH, Schinkel AH, Huitema AD. An integrated pharmacokinetic model for the influence of CYP3A4 expression on the in vivo disposition of lopinavir and its modulation by ritonavir. Journal of Pharmaceutical Sciences. 100: 2508-15. PMID 21491455 DOI: 10.1002/jps.22457  0.76
2011 Keizer RJ, Funahashi Y, Semba T, Wanders J, Beijnen JH, Schellens JH, Huitema AD. Evaluation of α2-integrin expression as a biomarker for tumor growth inhibition for the investigational integrin inhibitor E7820 in preclinical and clinical studies. The Aaps Journal. 13: 230-9. PMID 21387147 DOI: 10.1208/s12248-011-9260-2  0.84
2011 Keizer RJ, Schellens JH, Beijnen JH, Huitema AD. Pharmacodynamic biomarkers in model-based drug development in oncology. Current Clinical Pharmacology. 6: 30-40. PMID 21235464 DOI: 10.2174/157488411794941368  0.84
2011 Lagas JS, Wagenaar JF, Huitema AD, Hillebrand MJ, Koks CH, Gerdes VE, Brandjes DP, Beijnen JH. Lethal morphine intoxication in a patient with a sickle cell crisis and renal impairment: case report and a review of the literature. Human & Experimental Toxicology. 30: 1399-403. PMID 21056950 DOI: 10.1177/0960327110388962  0.8
2011 Keizer RJ, van Benten M, Beijnen JH, Schellens JH, Huitema AD. Piraña and PCluster: a modeling environment and cluster infrastructure for NONMEM. Computer Methods and Programs in Biomedicine. 101: 72-9. PMID 20627442 DOI: 10.1016/j.cmpb.2010.04.018  0.84
2011 Jansen RS, Rosing H, Schellens JH, Beijnen JH. Mass spectrometry in the quantitative analysis of therapeutic intracellular nucleotide analogs. Mass Spectrometry Reviews. 30: 321-43. PMID 20623700 DOI: 10.1002/mas.20280  1
2011 Soto E, Keizer RJ, Trocóniz IF, Huitema AD, Beijnen JH, Schellens JH, Wanders J, Cendrós JM, Obach R, Peraire C, Friberg LE, Karlsson MO. Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: two case studies. Investigational New Drugs. 29: 984-95. PMID 20449627 DOI: 10.1007/s10637-010-9437-z  1
2011 Lagas JS, Wilhelm AJ, Vos RM, van den Dool EJ, van der Heide Y, Huissoon S, Beijnen JH, Brandjes DP. Toxicokinetics of a dipyridamole (Persantin) intoxication: case report. Human & Experimental Toxicology. 30: 74-8. PMID 20375123 DOI: 10.1177/0960327110368696  1
2011 Appels NM, Bolijn MJ, van Eijndhoven MA, Stephens TC, Beijnen JH, Schellens JH. Characterization of the in vitro activity of AZD3409, a novel prenyl transferase inhibitor. Cancer Chemotherapy and Pharmacology. 67: 137-45. PMID 20229082 DOI: 10.1007/s00280-010-1300-6  0.84
2011 Jansen RS, Rosing H, Schellens JH, Beijnen JH. Deoxyuridine analog nucleotides in deoxycytidine analog treatment: secondary active metabolites? Fundamental & Clinical Pharmacology. 25: 172-85. PMID 20199587 DOI: 10.1111/j.1472-8206.2010.00823.x  1
2010 Calsteren KV, Verbesselt R, Devlieger R, De Catte L, Chai DC, Van Bree R, Heyns L, Beijnen J, Demarsin S, de Bruijn E, de Hoon J, Amant F. Transplacental transfer of paclitaxel, docetaxel, carboplatin, and trastuzumab in a baboon model. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. 20: 1456-64. PMID 21307819 DOI: 10.1111/IGC.0b013e3181fb18c8  0.72
2010 van den Broek I, Sparidans RW, Schellens JH, Beijnen JH. Specific Investigation of Sample Handling Effects on Protease Activities and Absolute Serum Concentrations of Various Putative Peptidome Cancer Biomarkers. Clinical Proteomics. 6: 115-127. PMID 21124649 DOI: 10.1007/s12014-010-9054-z  0.32
2010 Amant F, Deckers S, Van Calsteren K, Loibl S, Halaska M, Brepoels L, Beijnen J, Cardoso F, Gentilini O, Lagae L, Mir O, Neven P, Ottevanger N, Pans S, Peccatori F, et al. Breast cancer in pregnancy: recommendations of an international consensus meeting. European Journal of Cancer (Oxford, England : 1990). 46: 3158-68. PMID 20932740 DOI: 10.1016/j.ejca.2010.09.010  0.72
2010 Van Calsteren K, Verbesselt R, Beijnen J, Devlieger R, De Catte L, Chai DC, Van Bree R, Heyns L, de Hoon J, Amant F. Transplacental transfer of anthracyclines, vinblastine, and 4-hydroxy-cyclophosphamide in a baboon model. Gynecologic Oncology. 119: 594-600. PMID 20846713 DOI: 10.1016/j.ygyno.2010.08.019  0.72
2010 Keizer RJ, Gupta A, Mac Gillavry MR, Jansen M, Wanders J, Beijnen JH, Schellens JH, Karlsson MO, Huitema AD. A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080. Journal of Pharmacokinetics and Pharmacodynamics. 37: 347-63. PMID 20652729 DOI: 10.1007/s10928-010-9164-2  0.84
2010 Keizer RJ, Huitema AD, Schellens JH, Beijnen JH. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clinical Pharmacokinetics. 49: 493-507. PMID 20608753 DOI: 10.2165/11531280-000000000-00000  0.84
2010 Buikhuisen WA, Burgers JA, Vincent AD, Schellens JH, Beijnen JH, Smit EF, Joerger M. Pemetrexed pathway-associated germline polymorphisms: a useful tool for treatment individualization? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: e482-3; author reply. PMID 20606096 DOI: 10.1200/JCO.2010.29.1559  1
2010 van Waterschoot RA, ter Heine R, Wagenaar E, van der Kruijssen CM, Rooswinkel RW, Huitema AD, Beijnen JH, Schinkel AH. Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir. British Journal of Pharmacology. 160: 1224-33. PMID 20590614 DOI: 10.1111/j.1476-5381.2010.00759.x  0.76
2010 Ter Heine R, Mulder JW, van Gorp EC, Wagenaar JF, Beijnen JH, Huitema AD. Intracellular and plasma steady-state pharmacokinetics of raltegravir, darunavir, etravirine and ritonavir in heavily pre-treated HIV-infected patients. British Journal of Clinical Pharmacology. 69: 475-83. PMID 20573083 DOI: 10.1111/j.1365-2125.2010.03634.x  0.72
2010 Tran L, Baars JW, Aarden L, Beijnen JH, Huitema AD. Pharmacokinetics of rituximab in patients with CD20 positive B-cell malignancies. Human Antibodies. 19: 7-13. PMID 20555126 DOI: 10.3233/HAB-2010-0215  0.72
2010 Ter Heine R, Rosing H, Beijnen JH, Huitema AD. A less sensitive detector does not necessarily result in a less sensitive method: fast quantification of 13 antiretroviral analytes in plasma with liquid chromatography coupled with tandem mass spectrometry. Clinical Chemistry and Laboratory Medicine : Cclm / Fescc. 48: 1153-5. PMID 20482447 DOI: 10.1515/CCLM.2010.225  1
2010 de Vries NA, Bruggeman SW, Hulsman D, de Vries HI, Zevenhoven J, Buckle T, Hamans BC, Leenders WP, Beijnen JH, van Lohuizen M, Berns AJ, van Tellingen O. Rapid and robust transgenic high-grade glioma mouse models for therapy intervention studies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 3431-41. PMID 20472681 DOI: 10.1158/1078-0432.CCR-09-3414  0.52
2010 van den Berg JH, Oosterhuis K, Beijnen JH, Nuijen B, Haanen JB. DNA vaccination in oncology: current status, opportunities and perspectives. Current Clinical Pharmacology. 5: 218-25. PMID 20406167 DOI: 10.2174/157488410791498734  1
2010 Jansen RS, Rosing H, Schellens JH, Beijnen JH. Facile small scale synthesis of nucleoside 5'-phosphate mixtures. Nucleosides, Nucleotides & Nucleic Acids. 29: 14-26. PMID 20391189 DOI: 10.1080/15257770903451546  1
2010 Israels T, Damen CW, Cole M, van Geloven N, Boddy AV, Caron HN, Beijnen JH, Molyneux EM, Veal GJ. Malnourished Malawian patients presenting with large Wilms tumours have a decreased vincristine clearance rate. European Journal of Cancer (Oxford, England : 1990). 46: 1841-7. PMID 20382523 DOI: 10.1016/j.ejca.2010.03.002  1
2010 Jansen RS, Rosing H, Kromdijk W, ter Heine R, Schellens JH, Beijnen JH. Simultaneous quantification of emtricitabine and tenofovir nucleotides in peripheral blood mononuclear cells using weak anion-exchange liquid chromatography coupled with tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 878: 621-7. PMID 20122883 DOI: 10.1016/j.jchromb.2010.01.002  1
2010 van den Berg JH, Nuijen B, Schumacher TN, Haanen JB, Storm G, Beijnen JH, Hennink WE. Synthetic vehicles for DNA vaccination. Journal of Drug Targeting. 18: 1-14. PMID 19814658 DOI: 10.3109/10611860903278023  1
2010 van den Berg JH, Oosterhuis K, Hennink WE, Storm G, van der Aa LJ, Engbersen JF, Haanen JB, Beijnen JH, Schumacher TN, Nuijen B. Shielding the cationic charge of nanoparticle-formulated dermal DNA vaccines is essential for antigen expression and immunogenicity. Journal of Controlled Release : Official Journal of the Controlled Release Society. 141: 234-40. PMID 19751778 DOI: 10.1016/j.jconrel.2009.09.005  1
2010 Vainchtein LD, Rosing H, Schellens JH, Beijnen JH. A new, validated HPLC-MS/MS method for the simultaneous determination of the anti-cancer agent capecitabine and its metabolites: 5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluorouridine, 5-fluorouracil and 5-fluorodihydrouracil, in human plasma. Biomedical Chromatography : Bmc. 24: 374-86. PMID 19650151 DOI: 10.1002/bmc.1302  1
2010 van den Berg JH, Quaak SG, Beijnen JH, Hennink WE, Storm G, Schumacher TN, Haanen JB, Nuijen B. Lipopolysaccharide contamination in intradermal DNA vaccination: toxic impurity or adjuvant? International Journal of Pharmaceutics. 390: 32-6. PMID 19576975 DOI: 10.1016/j.ijpharm.2009.06.031  1
2010 Oostendorp RL, Witteveen PO, Schwartz B, Vainchtein LD, Schot M, Nol A, Rosing H, Beijnen JH, Voest EE, Schellens JH. Dose-finding and pharmacokinetic study of orally administered indibulin (D-24851) to patients with advanced solid tumors. Investigational New Drugs. 28: 163-70. PMID 19404582 DOI: 10.1007/s10637-009-9244-6  1
2010 Zandvliet AS, Karlsson MO, Schellens JH, Copalu W, Beijnen JH, Huitema AD. Two-stage model-based clinical trial design to optimize phase I development of novel anticancer agents. Investigational New Drugs. 28: 61-75. PMID 19198760 DOI: 10.1007/s10637-008-9216-2  0.84
2009 ter Heine R, Beijnen JH, Huitema AD. Bioanalytical issues in patient-friendly sampling methods for therapeutic drug monitoring: focus on antiretroviral drugs. Bioanalysis. 1: 1329-38. PMID 21083054 DOI: 10.4155/bio.09.124  0.72
2009 CömezoÄŸlu SN, Ly VT, Zhang D, Humphreys WG, Bonacorsi SJ, Everett DW, Cohen MB, Gan J, Beumer JH, Beijnen JH, Schellens HM, Lappin G. Biotransformation profiling of [(14)C]ixabepilone in human plasma, urine and feces samples using accelerator mass spectrometry (AMS). Drug Metabolism and Pharmacokinetics. 24: 511-22. PMID 20045986 DOI: 10.2133/DMPK.24.511  1
2009 Tran L, Beijnen JH, Huitema AD. The preparation of radiolabeled monoclonal antibodies for human use. Human Antibodies. 18: 145-56. PMID 19996529 DOI: 10.3233/HAB-2009-0211  0.72
2009 Gast MC, van Dulken EJ, van Loenen TK, Kingma-Vegter F, Westerga J, Flohil CC, Knol JC, Jimenez CR, van Gils CH, Wessels LF, Schellens JH, Beijnen JH. Detection of breast cancer by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry tissue and serum protein profiling. The International Journal of Biological Markers. 24: 130-41. PMID 19787623 DOI: 10.5301/JBM.2009.3475  0.84
2009 Lankheet AG, Hillebrand MJ, Langenberg MH, Rosing H, Huitema AD, Voest EE, Schellens JH, Beijnen JH. A validated assay for the quantitative analysis of vatalanib in human EDTA plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 877: 3625-30. PMID 19762293 DOI: 10.1016/j.jchromb.2009.09.001  1
2009 Damen CW, Chen W, Chakraborty AB, van Oosterhout M, Mazzeo JR, Gebler JC, Schellens JH, Rosing H, Beijnen JH. Electrospray ionization quadrupole ion-mobility time-of-flight mass spectrometry as a tool to distinguish the lot-to-lot heterogeneity in N-glycosylation profile of the therapeutic monoclonal antibody trastuzumab. Journal of the American Society For Mass Spectrometry. 20: 2021-33. PMID 19744865 DOI: 10.1016/j.jasms.2009.07.017  1
2009 Jansen RS, Rosing H, Schellens JH, Beijnen JH. Simultaneous quantification of 2',2'-difluorodeoxycytidine and 2',2'-difluorodeoxyuridine nucleosides and nucleotides in white blood cells using porous graphitic carbon chromatography coupled with tandem mass spectrometry. Rapid Communications in Mass Spectrometry : Rcm. 23: 3040-50. PMID 19705384 DOI: 10.1002/rcm.4212  1
2009 Jansen RS, Rosing H, Schellens JH, Beijnen JH. Protein versus DNA as a marker for peripheral blood mononuclear cell counting. Analytical and Bioanalytical Chemistry. 395: 863-7. PMID 19685233 DOI: 10.1007/s00216-009-3022-3  1
2009 Teunissen SF, Rosing H, Koornstra RH, Linn SC, Schellens JH, Schinkel AH, Beijnen JH. Development and validation of a quantitative assay for the analysis of tamoxifen with its four main metabolites and the flavonoids daidzein, genistein and glycitein in human serum using liquid chromatography coupled with tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 877: 2519-29. PMID 19589736 DOI: 10.1016/j.jchromb.2009.06.029  1
2009 Quaak SG, van den Berg JH, Oosterhuis K, Beijnen JH, Haanen JB, Nuijen B. DNA tattoo vaccination: effect on plasmid purity and transfection efficiency of different topoisoforms. Journal of Controlled Release : Official Journal of the Controlled Release Society. 139: 153-9. PMID 19580829 DOI: 10.1016/j.jconrel.2009.06.033  0.8
2009 ter Heine R, Hillebrand MJ, Rosing H, van Gorp EC, Mulder JW, Beijnen JH, Huitema AD. Identification and profiling of circulating metabolites of atazanavir, a HIV protease inhibitor. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 37: 1826-40. PMID 19546238 DOI: 10.1124/dmd.109.028258  1
2009 Gast MC, Van Gils CH, Wessels LF, Harris N, Bonfrer JM, Rutgers EJ, Schellens JH, Beijnen JH. Serum protein profiling for diagnosis of breast cancer using SELDI-TOF MS. Oncology Reports. 22: 205-13. PMID 19513525 DOI: 10.3892/OR_00000426  0.84
2009 Oostendorp RL, Huitema A, Rosing H, Jansen RS, Ter Heine R, Keessen M, Beijnen JH, Schellens JH. Coadministration of ritonavir strongly enhances the apparent oral bioavailability of docetaxel in patients with solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 4228-33. PMID 19509162 DOI: 10.1158/1078-0432.CCR-08-2944  1
2009 Gast MC, van Gils CH, Wessels LF, Harris N, Bonfrer JM, Rutgers EJ, Schellens JH, Beijnen JH. Influence of sample storage duration on serum protein profiles assessed by surface-enhanced laser desorption/ionisation time-of-flight mass spectrometry (SELDI-TOF MS). Clinical Chemistry and Laboratory Medicine : Cclm / Fescc. 47: 694-705. PMID 19416081 DOI: 10.1515/CCLM.2009.151  0.84
2009 Brouwers EE, Huitema AD, Boogerd W, Beijnen JH, Schellens JH. Persistent neuropathy after treatment with cisplatin and oxaliplatin. Acta Oncologica (Stockholm, Sweden). 48: 832-41. PMID 19308757 DOI: 10.1080/02841860902806609  0.84
Show low-probability matches.